var docs;if (!docs) docs =[]; docs["85"]={"8501":"<p><b>Title</b> Beta2-Agonists / Corticosteroids</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Corticosteroids may enhance the hypokalemic effect of Beta2-Agonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required for most patients. Patients using higher doses and/or systemic (vs. inhaled) administration of either drug may be at a higher risk for a clinically significant interaction and may warrant increased monitoring for hypokalemia.</p>\n<div>\n <p><b>Beta2-Agonists Interacting Members</b> Albuterol, Arformoterol, Bambuterol, Fenoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Pirbuterol, Ritodrine, Salmeterol, Terbutaline, Tulobuterol, Vilanterol</p>\n <p><b>Corticosteroids Interacting Members</b> Beclomethasone (Nasal), Beclomethasone (Oral Inhalation), Beclomethasone (Topical), Betamethasone (Nasal), Betamethasone (Ophthalmic), Betamethasone (Systemic), Budesonide (Nasal), Budesonide (Oral Inhalation), Budesonide (Systemic), Ciclesonide (Nasal), Ciclesonide (Oral Inhalation), Clobetasone, Corticotropin, Cortisone, Deflazacort, Dexamethasone (Ophthalmic), Dexamethasone (Systemic), Difluprednate, Fludrocortisone, Flunisolide (Nasal), Flunisolide (Oral Inhalation), Fluocinolone (Ophthalmic), Fluocinonide, Flurandrenolide, Fluticasone (Nasal), Fluticasone (Oral Inhalation), Hydrocortisone (Systemic), Loteprednol, Medrysone, MethylPREDNISolone, Mometasone (Nasal), Mometasone (Oral Inhalation), PrednisoLONE (Ophthalmic), PrednisoLONE (Systemic), PrednisoLONE (Topical), PredniSONE, Rimexolone, Tixocortol Pivalate, Triamcinolone (Nasal), Triamcinolone (Ophthalmic), Triamcinolone (Systemic)<br><b>Exceptions</b> Alclometasone, Amcinonide, Betamethasone (Topical), Budesonide (Topical), Clobetasol, Clocortolone, Desonide, Desoximetasone, Diflorasone, Diflucortolone, Fluocinolone (Topical), Fluorometholone, Fluticasone (Topical), Halcinonide, Halobetasol, Hydrocortisone (Ophthalmic), Hydrocortisone (Topical), Mometasone (Topical), Prednicarbate, Triamcinolone (Topical)</p>\n</div> \n<p><b>Discussion</b> Conflicting evidence exists regarding the risk of hypokalemia in concomitant use of corticosteroids and beta2-agonists. The risk of hypokalemia appears to be greater with oral rather than inhaled corticosteroid. <br><br>No clinically significant reduction in serum potassium level was found in several studies of inhaled combination products with a long-acting beta2-agonist and a corticosteroid in randomized trials of patients with asthma or chronic obstructive pulmonary disease.<sup>1,2,3</sup> In addition, no clinically significant decrease in serum potassium level was found in studies of different inhaled combination products (budesonide/formoterol and beclomethasone/formoterol) in patients with asthma.<sup>4,5</sup><br><br>In contrast, oral prednisone 30 mg significantly reduced serum potassium concentrations when used together with inhaled beta2-agonists (5 mg albuterol or fenoterol) in a randomized study of 24 young, healthy male volunteers.<sup>6</sup> The addition of oral prednisone was associated with an average maximum reduction in serum potassium of 0.44 mEq/L and 0.87 mEq/L, respectively, beyond what was seen with either albuterol or fenoterol alone.<br><br>The overall clinical significance of this interaction is uncertain, but the labeling for at least one beta2-agonist does caution about this combination.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lotvall J, Bateman ED, Bleecker ER, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. <i>Eur Respir J</i>. 2012;40(3):570-579. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22362859\">[PubMed 22362859]</a></p>\n<p>2. Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. <i>Clin Ther</i>. 2012;34(8):1655-1666. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22789766\">[PubMed 22789766]</a></p>\n<p>3. Busse WW, O’Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the B2 agonist vilanterol administered once daily for 52 weeks in patients <u> &gt; </u> 12 years old with asthma: a randomised trial. <i>Thorax</i>. 2013;68(6):513-520. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23440247\">[PubMed 23440247]</a></p>\n<p>4. Berger WE, Leflein JG, Geller DE, et al. The safety and clinical benefit of budesonide/formoterol pressurized metered-dose inhaler versus budesonide alone in children. <i>Allergy Asthma Proc</i>. 2010;31(1):26-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20167143\">[PubMed 20167143]</a></p>\n<p>5. Singh D, Piccinno A, Borrill Z, et al. Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients. <i>Pulm Pharmacol Ther</i>. 2008;21(3):551-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18321744\">[PubMed 18321744]</a></p>\n<p>6. Taylor DR, Wilkins GT, Herbison GP, Flannery EM. Interaction between corticosteroid and B-agonist drugs. Biochemical and cardiovascular effects in normal subjects. <i>Chest</i>. 1992;102(2):519-524 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1353717\">[PubMed 1353717]</a></p>\n<p>7. <i>Bambec</i> (bambuterol) [summary of product characteristics]. Luton, Bedfordshire, United Kingdom; AstraZeneca UK Limited; March 2011.</p>\n<p>8. <i>Bambec</i> (bambuterol) [summary of product characteristics (Singapore)]. Cabuyao, Laguna, Philippines; Interphil Laboratories, Inc.; January 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8502":"<p><b>Title</b> Finasteride / Saw Palmetto</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Saw Palmetto may enhance the adverse/toxic effect of Finasteride. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Though the exact mechanism(s) by which saw palmetto works is uncertain, available evidence supports a possible additive or synergistic effect with 5-alpha-reductase inhibitors, which impair the conversion of testosterone to dihydrotestosterone (DHT). In vitro studies have shown that saw palmetto is a potent inhibitor of both type I and II 5-alpha reductase isoenzymes.<sup>1</sup> Additionally, saw palmetto demonstrates inhibition of DHT binding to the cytosolic androgen receptor in prostate cells.<sup>2</sup> In a systemic review of 40 articles (26 randomized controlled trials, 4 non-randomized controlled trials, 6 uncontrolled trials, and 4 case reports/series), some reported adverse events of saw palmetto were similar to those reported with use of 5-alpha-reductase inhibitors such as finasteride and dutasteride, including decreased libido, impotence, and ejaculation disorder, among others.<sup>3</sup><br><br>The clinical significance of this possible interaction is uncertain but is expected to be low. Although saw palmetto may work somewhat similarly to finasteride and dutasteride, its actions appear to be less potent, and the reported incidence of side effects such as decreased libido or impotence is generally less than with finasteride or dutasteride,<sup>4,5</sup> though the number and quality of direct comparisons are somewhat limited.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. <i>Prostate</i>. 1999;40(4):232-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10420151\">[PubMed 10420151]</a></p>\n<p>2. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. <i>Prostate</i>. 1998;37(2):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9759701\">[PubMed 9759701]</a></p>\n<p>3. Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. <i>Drug Saf</i>. 2009;32(8):637-647. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19591529\">[PubMed 19591529]</a></p>\n<p>4. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. <i>JAMA</i>. 1998;280(18):1604-1609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9820264\">[PubMed 9820264]</a></p>\n<p>5. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. <i>Eur Urol</i>. 2005;48(2):269-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15939527\">[PubMed 15939527]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8503":"<p><b>Title</b> Dutasteride / Saw Palmetto</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Saw Palmetto may enhance the adverse/toxic effect of Dutasteride. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Though the exact mechanism(s) by which saw palmetto works is uncertain, available evidence supports a possible additive or synergistic effect with 5-alpha-reductase inhibitors, which impair the conversion of testosterone to dihydrotestosterone (DHT). In vitro studies have shown that saw palmetto is a potent inhibitor of both type I and II 5-alpha reductase isoenzymes.<sup>1</sup> Additionally, saw palmetto demonstrates inhibition of DHT binding to the cytosolic androgen receptor in prostate cells.<sup>2</sup> In a systemic review of 40 articles (26 randomized controlled trials, 4 non-randomized controlled trials, 6 uncontrolled trials, and 4 case reports/series), some reported adverse events of saw palmetto were similar to those reported with use of 5-alpha-reductase inhibitors such as finasteride and dutasteride, including decreased libido, impotence, and ejaculation disorder, among others.<sup>3</sup><br><br>The clinical significance of this possible interaction is uncertain but is expected to be low. Although saw palmetto may work somewhat similarly to finasteride and dutasteride, its actions appear to be less potent, and the reported incidence of side effects such as decreased libido or impotence is generally less than with finasteride or dutasteride,<sup>4,5</sup> though the number and quality of direct comparisons are somewhat limited.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bayne CW, Donnelly F, Ross M, Habib FK. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. <i>Prostate</i>. 1999;40(4):232-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10420151\">[PubMed 10420151]</a></p>\n<p>2. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. <i>Prostate</i>. 1998;37(2):77-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9759701\">[PubMed 9759701]</a></p>\n<p>3. Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. <i>Drug Saf</i>. 2009;32(8):637-647. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19591529\">[PubMed 19591529]</a></p>\n<p>4. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. <i>JAMA</i>. 1998;280(18):1604-1609. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9820264\">[PubMed 9820264]</a></p>\n<p>5. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. <i>Eur Urol</i>. 2005;48(2):269-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15939527\">[PubMed 15939527]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8504":"<p><b>Title</b> Meloxicam / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Itraconazole may decrease the serum concentration of Meloxicam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced effects of meloxicam in patients treated with itraconazole. Meloxicam dose adjustment or use of an alternative anti-inflammatory agent may be necessary.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, coadministration of itraconazole (200 mg daily for 4 days) decreased the maximum concentration and AUC of meloxicam (15 mg single oral dose given 1 h after the final itraconazole dose) by approximately 64% and 37%, respectively.<sup>1</sup> Meloxicam effects on inhibition of thromboxane B2 were abolished. The mechanism of this interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hynninen VV, Olkkola KT, Bertilsson L, et al. Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. <i>Antimicrob Agents Chemother</i>. 2009;53(2):587-592. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19015346\">[PubMed 19015346]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8519":"<p><b>Title</b> Telaprevir / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may decrease the serum concentration of Telaprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of telaprevir and tipranavir/ritonavir is not recommended.</p> \n<p><b>Discussion</b> Specific data regarding the use of this combination are not available, but based on data with other anti-HIV protease inhibitors, the tipranavir prescribing information cautions that coadministration of tipranavir/ritonavir with telaprevir is not recommended.<sup>1</sup> According to the telaprevir prescribing information, telaprevir concentrations have been significantly reduced when used in combination with atazanavir/ritonavir, darunavir/ritonavir, fosamprenavir/ritonavir, lopinavir/ritonavir and multiple-doses of ritonavir (100 mg twice/day).<sup>2</sup> Concentrations of the anti-HIV protease inhibitors have varied with the combination, with some increasing, some decreasing, and some remaining mostly unchanged.<br><br>The mechanism for any potential interaction between tipranavir/ritonavir and boceprevir is uncertain, but alteration of telaprevir metabolism by CYP3A may be at least partially involved. The manner in which tipranavir alone affects CYP3A4 is uncertain, but it has been characterized as primarily a CYP3A inducer.<sup>3</sup> However, since tipranavir must always be given with ritonavir, which is a potent CYP3A inhibitor, the net effect is expected to be CYP3A4 inhibition.<sup>1,3</sup> Despite this, studies of tipranavir/ritonavir used together with other anti-HIV protease inhibitors have largely demonstrated reduced concentrations of the other protease inhibitors, more suggestive of CYP3A induction than inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. <i>Incivek</i> (telaprevir) [prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; October 2013.</p>\n<p>3. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir: Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814. http://www.fda.gov/ohrms/DOCKETS/ac/05/briefing/2005-4139b1-02-boehringer.pdf. Published April 19, 2005. Accessed June 4, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8520":"<p><b>Title</b> Tipranavir / Boceprevir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may decrease the serum concentration of Boceprevir. Boceprevir may decrease the serum concentration of Tipranavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Coadministration of boceprevir and tipranavir/ritonavir is not recommended.</p> \n<p><b>Discussion</b> Specific data regarding the use of this combination are not available, but based on data with other anti-HIV protease inhibitors, the tipranavir prescribing information cautions that coadministration of tipranavir/ritonavir with boceprevir is not recommended.<sup>1</sup> According to the boceprevir prescribing information, boceprevir concentrations have been significantly reduced when used in combination with darunavir/ritonavir, lopinavir/ritonavir and ritonavir.<sup>2</sup> Concentrations of the anti-HIV protease inhibitors have also generally decreased with the combination.<br><br>The mechanism for any potential interaction between tipranavir/ritonavir and boceprevir is uncertain, but alteration of boceprevir metabolism by CYP3A may be at least partially involved. The manner in which tipranavir alone affects CYP3A4 is uncertain, but it has been characterized as primarily a CYP3A inducer.<sup>3</sup> However, since tipranavir must always be given with ritonavir, which is a potent CYP3A inhibitor, the net effect is expected to be CYP3A4 inhibition.<sup>1,3</sup> Despite this, studies of tipranavir/ritonavir used together with other anti-HIV protease inhibitors have largely demonstrated reduced concentrations of the other protease inhibitors, more suggestive of CYP3A induction than inhibition.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. <i>Victrelis</i> (boceprevir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; April 2014.</p>\n<p>3. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir: Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814. http://www.fda.gov/ohrms/DOCKETS/ac/05/briefing/2005-4139b1-02-boehringer.pdf. Published April 19, 2005. Accessed June 4, 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8521":"<p><b>Title</b> Fosphenytoin / Miconazole (Oral)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Miconazole (Oral) may increase the serum concentration of Fosphenytoin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased serum phenytoin concentrations and phenytoin toxicity if these agents are used in combination.</p> \n<p><b>Discussion</b> Although oral miconazole is generally considered nonabsorbed, the prescribing information for miconazole does warn that systemic drug interactions are possible, with an emphasis on CYP2C9- and CYP3A-metabolized drugs, and a specific caution concerning concurrent phenytoin.<sup>1</sup> The prescribing information for phenytoin also lists miconazole as a medication likely to interact with phenytoin.<sup>2</sup><br> <br>A case report describes a 51-year-old male who experienced phenytoin intoxication and supratherapeutic serum phenytoin concentrations following the initiation of intravenous miconazole.<sup>3</sup> There are no reports describing an interaction between phenytoin and oral miconazole.<br><br>The likely mechanism for this reported interaction is miconazole-mediated inhibition of the CYP2C9 and 2C19 metabolism of phenytoin. Miconazole has been shown to be a highly potent inhibitor of CYP2C9 and CYP2C19.<sup>4</sup> However, in vivo concentrations are unlikely to reach the stated inhibitory concentrations with standard use of oral miconazole in most patients, as only 3% of patients had measurable plasma concentrations of miconazole with recommended use of the oral buccal tablet.<sup>1,5</sup> This, along with the lack of studies involving concurrent use of oral miconazole and phenytoin in patients, makes the clinical significance of this potential interaction unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Oravig</i> (miconazole). [prescribing information] Cary, NC: Praelia Pharmaceuticals, Inc; August 2012.</p>\n<p>2. <i>Cerebyx</i> (fosphenytoin). [prescribing information] New York, NY: Pfizer; June 2014.</p>\n<p>3. Rolan PE, Somogyi AA, Drew MJ, Cobain WG, South D, Bochner F. Phenytoin intoxication during treatment with parenteral miconazole. <i>Br Med J (Clin Res Ed)</i>. 1983;287(6407):1760. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6416579\">[PubMed 6416579]</a></p>\n<p>4. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. <i>Biol Pharm Bull</i>. 2005;28(9):1805-1808. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141567\">[PubMed 16141567]</a></p>\n<p>5. Cardot JM, Chaumont C, Dubray C, Costantini D, Aiache JM. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. <i>Br J Clin Pharmacol</i>. 2004;58(4):345-351. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15373926\">[PubMed 15373926]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8523":"<p><b>Title</b> Fluticasone (Oral Inhalation) / Tipranavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Fluticasone (Oral Inhalation). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of nasal or inhaled fluticasone with tipranavir/ritonavir is not recommended.</p> \n<p><b>Discussion</b> Although specific information regarding this combination is not available, the tipranavir prescribing information cautions that use of nasal or inhaled fluticasone with tipranavir/ritonavir is not recommended due to the risk for increased fluticasone concentrations and effects.<sup>1</sup><br><br>Whether this concern is primarily related to tipranavir, ritonavir (which must be used with tipranavir to “boost” tipranavir concentrations), or both is uncertain. The degree to which tipranavir alone is capable of inhibiting CYP3A4, which is largely responsible for fluticasone metabolism, is uncertain, but appears to be at most modest, as tipranavir alone may even induce CYP3A4.<sup>2</sup> Nevertheless, as tipranavir must always be given with ritonavir, the net effect is expected to be CYP3A4 inhibition.<sup>1,2</sup> Ritonavir alone is considered a strong inhibitor of CYP3A4, and several case reports describe patients who developed adrenal suppression and/or Cushing syndrome with concurrent use of ritonavir (often in low boosting doses together with another protease inhibitor) and inhaled fluticasone.<sup>3,4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir: Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814. http://www.fda.gov/ohrms/DOCKETS/ac/05/briefing/2005-4139b1-02-boehringer.pdf. Published April 19, 2005. Accessed June 4, 2014.</p>\n<p>3. Mahlab-Guri K, Asher I, Gradstein S, et al. Inhaled fluticasone causes iatrogenic Cushing's syndrome in patients treated with ritonavir. <i>J Asthma</i>. 2011;48(8):860-863. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21854345\">[PubMed 21854345]</a></p>\n<p>4. Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. <i>J Asthma</i>. 2010;47(7):830-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20653496\">[PubMed 20653496]</a></p>\n<p>5. Valin N, De Castro N, Garrait V, Bergeron A, Bouche C, Molina JM. Iatrogenic Cushing's syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature. <i>J Int Assoc Physicians AIDS Care (Chic)</i>. 2009;8(2):113-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19270151\">[PubMed 19270151]</a></p>\n<p>6. Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM. Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir. <i>Ann Pharmacother</i>. 2007;41(7):1306-1309. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17535841\">[PubMed 17535841]</a></p>\n<p>7. St Germain RM, Yigit S, Wells L, Girotto JE, Salazar JC. Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent. <i>AIDS Patient Care STDS</i>. 2007;21(6):373-377. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17594245\">[PubMed 17594245]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8524":"<p><b>Title</b> Tadalafil / Tipranavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Recommendations for the specific management of this interaction vary according to whether tadalafil is being used for treatment of erectile dysfunction or pulmonary hypertension.</p></li>\n <li><p><b>International labeling</b>: The overall significance of this interaction and recommendations regarding its management both differ between U.S. and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tipranavir may increase the serum concentration of Tadalafil. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Recommendations regarding use of tadalafil in patients also receiving tipranavir/ritonavir may vary based on indication and/or international labeling. The tipranavir product labeling recommendations include: limiting tadalafil to a maximum of 2.5 mg/day (for once daily use) or 10 mg per 72-hours (for use as needed) when used for treatment of erectile dysfunction in patients also receiving tipranavir/ritonavir, decreasing the starting tadalafil dose to 20 mg/day, and increasing to 40 mg/day as tolerated when used for treatment of pulmonary hypertension in patients who have been taking tipranavir/ritonavir for at least 1 week, and avoiding use of tadalafil during initiation of tipranavir/ritonavir therapy, stopping tadalafil at least 24 hours prior to tipranavir/ritonavir initiation.<br><br>Of note, the Tadalafil Canadian product labeling recommendations differ with respect to use of tadalafil with ritonavir (or tipranavir/ritonavir), and include: avoiding use of tadalafil in patients with pulmonary hypertension who are also receiving ritonavir, and treatment of erectile dysfunction with tadalafil doses of 2.5-5 mg/day (once daily use) or 10 mg at minimum intervals of 48 hours (maximum of 3 doses per week) with the option to increase dose to 20 mg if the lower dosage is tolerated but ineffective (for use as needed).</p> \n<p><b>Discussion</b> Although specific information regarding this particular combination are not available, the tipranavir prescribing information cautions that tadalafil dose/therapy adjustments are likely needed with concurrent use of tadalafil and tipranavir/ritonavir.<sup>1</sup><br><br>This concern seems more likely due to ritonavir, which must always be used with tipranavir, than with tipranavir itself since the degree to which tipranavir alone is capable of inhibiting the CYP3A4-mediated metabolism of tadalafil is uncertain, but appears to be at most modest, as tipranavir alone may even induce CYP3A4.<sup>2</sup> Nevertheless, as tipranavir must always be given with ritonavir, the net effect is expected to be CYP3A4 inhibition.<sup>1,2</sup> Ritonavir alone is considered a strong inhibitor of CYP3A4, and the tadalafil dosing recommendations in the tipranavir prescribing information mirror those for use with ritonavir in the tadalafil U.S. prescribing information.<sup>3,4</sup> In contrast, the Candian tadalafil product monographs contain stronger recommendations, advising avoidance of the combination when tadalafil is being used to treat pulmonary hypertension.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aptivus</i> (tipranavir) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir: Anti-viral Drugs Advisory Committee (AVDAC) Briefing Document. NDA 21-814. http://www.fda.gov/ohrms/DOCKETS/ac/05/briefing/2005-4139b1-02-boehringer.pdf. Published April 19, 2005. Accessed June 4, 2014.</p>\n<p>3. <i>Cialis</i> (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; April 2009.</p>\n<p>4. <i>Adcirca</i> (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2009.</p>\n<p>5. <i>Adcirca</i> (tadalfil) [product monograph]. Toronto, Ontario: Eli Lilly Canada Inc.; May 2010.</p>\n<p>6. <i>Cialis</i> (tadalfil) [product monograph]. Toronto, Ontario: Eli Lilly Canada Inc.; March 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8525":"<p><b>Title</b> Warfarin / Entacapone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Entacapone may increase the serum concentration of Warfarin. Specifically, entacapone may increase levels of the less potent R-enantiomer of warfarin <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects (eg, INR, signs and symptoms of bleeding) when entacapone is initiated or the dose is increased.</p> \n<p><b>Discussion</b> In a pharmacokinetic study conducted in 12 healthy volunteers, the addition of entacapone (200 mg four times a day) resulted in a 18% increase in the AUC of R-warfarin.<sup>1</sup> Entacapone had no effect on the pharmacokinetics of the more potent enantiomer, S-warfarin. INR values increased an average of 13%. Although the results of this study suggest a significant interaction between entacapone and warfarin is unlikely to occur, product labeling for entacapone states that post-marketing reports of significant INR elevations have occurred.<sup>2</sup> Monitoring of INR is recommended when entacapone is initiated in patients taking warfarin.<br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady state pharmacokinetics and pharmacodynamics of warfarin. <i>Br J Clin Pharmacol</i>. 2002;53(5):485-491. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11994054\">[PubMed 11994054]</a></p>\n<p>2. <i>Comtan</i> (entacapone) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8526":"<p><b>Title</b> PACLitaxel (Conventional) / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Ritonavir): This interaction is likely of less clinical significance with ritonavir-boosted atazanavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of PACLitaxel (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of paclitaxel or other narrow therapeutic index CYP2C8 substrates with atazanavir without concurrent ritonavir is not recommended. If paclitaxel is used with ritonavir-boosted atazanavir, no significant interaction is expected according to the atazanavir prescribing information.</p> \n<p><b>Discussion</b> Specific data regarding concurrent use of atazanavir and paclitaxel are not available, but data with the CYP2C8 substrate rosiglitazone appear to support the recommendations in the atazanavir prescribing information.<sup>1</sup><br><br>The rosiglitazone AUC was an average of 35% higher with concurrent atazanavir in a study of 14 subjects who were given rosiglitazone (4 mg, single dose) on day 6 of atazanavir 400 mg/day.<sup>1</sup> In contrast, the rosiglitazone AUC was an average of 17% lower with concurrent atazanavir/ritonavir in a study of 14 subjects who were given rosiglitazone (4 mg, single dose) on day 10 of atazanavir/ritonavir 300 mg/100 mg once daily.<sup>1</sup><br><br>The mechanism for this interaction is uncertain, but atazanavir inhibition of the CYP2C8-mediated metabolism of rosiglitazone and other CYP2C8 substrates appears to be at least partially responsible. Why concurrent use of ritonavir would lessen the magnitude and significance of the interaction is unknown as ritonavir-boosted atazanavir (at 300 mg/100 mg daily dose) yields similar or greater systemic atazanavir exposure than does atazanavir (400 mg daily) without ritonavir.<sup>1</sup> It is possible that ritonavir itself modifies this interaction by altering CYP2C8 activity.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p>2. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. <i>Drug Metab Dispos</i>. 2007;35(10):1853-1859. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17639026\">[PubMed 17639026]</a></p>\n<p>3. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. <i>J Clin Pharmacol</i>. 2005;45(1):68-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15601807\">[PubMed 15601807]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8527":"<p><b>Title</b> Repaglinide / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Ritonavir): This interaction is likely of less clinical significance with ritonavir-boosted atazanavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Repaglinide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of repaglinide or other narrow therapeutic index CYP2C8 substrates with atazanavir without concurrent ritonavir is not recommended. If repaglinide is used with ritonavir-boosted atazanavir, no significant interaction is expected according to the atazanavir prescribing information.</p> \n<p><b>Discussion</b> Specific data regarding concurrent use of atazanavir and repaglinide are not available, but data with the CYP2C8 substrate rosiglitazone appear to support the recommendations in the atazanavir prescribing information.<sup>1</sup><br><br>The rosiglitazone AUC was an average of 35% higher with concurrent atazanavir in a study of 14 subjects who were given rosiglitazone (4 mg, single dose) on day 6 of atazanavir 400 mg/day.<sup>1</sup> In contrast, the rosiglitazone AUC was an average of 17% lower with concurrent atazanavir/ritonavir in a study of 14 subjects who were given rosiglitazone (4 mg, single dose) on day 10 of atazanavir/ritonavir 300 mg/100 mg once daily.<sup>1</sup><br><br>The mechanism for this interaction is uncertain, but atazanavir inhibition of the CYP2C8-mediated metabolism of rosiglitazone and other CYP2C8 substrates appears to be at least partially responsible. Why concurrent use of ritonavir would lessen the magnitude and significance of the interaction is unknown as ritonavir-boosted atazanavir (at 300 mg/100 mg daily dose) yields similar or greater systemic atazanavir exposure than does atazanavir (400 mg daily) without ritonavir.<sup>1</sup> It is possible that ritonavir itself modifies this interaction by altering CYP2C8 activity.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p>2. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. <i>Drug Metab Dispos</i>. 2007;35(10):1853-1859. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17639026\">[PubMed 17639026]</a></p>\n<p>3. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. <i>J Clin Pharmacol</i>. 2005;45(1):68-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15601807\">[PubMed 15601807]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8528":"<p><b>Title</b> Rosiglitazone / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Ritonavir): This interaction is likely of less clinical significance with ritonavir-boosted atazanavir than with unboosted atazanavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Rosiglitazone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to rosiglitazone closely if used together with unboosted atazanavir (i.e., without ritonavir), particularly when starting or stopping atazanavir. If rosiglitazone is used with ritonavir-boosted atazanavir, no significant interaction is expected according to the atazanavir prescribing information.</p> \n<p><b>Discussion</b> The rosiglitazone AUC was an average of 35% higher with concurrent atazanavir in a study of 14 subjects who were given rosiglitazone (4 mg, single dose) on day 6 of atazanavir 400 mg/day.<sup>1</sup> In contrast, the rosiglitazone AUC was an average of 17% lower with concurrent atazanavir/ritonavir in a study of 14 subjects who were given rosiglitazone (4 mg, single dose) on day 10 of atazanavir/ritonavir 300 mg/100 mg once daily.<sup>1</sup><br><br>The mechanism for this interaction is uncertain, but atazanavir inhibition of the CYP2C8-mediated metabolism of rosiglitazone appears to be at least partially responsible. Why concurrent use of ritonavir would lessen the magnitude and significance of the interaction is unknown as ritonavir-boosted atazanavir (at 300 mg/100 mg daily dose) yields similar or greater systemic atazanavir exposure than does atazanavir (400 mg daily) without ritonavir.<sup>1</sup> It is possible that ritonavir itself modifies this interaction by altering CYP2C8 activity.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p>2. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. <i>Drug Metab Dispos</i>. 2007;35(10):1853-1859. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17639026\">[PubMed 17639026]</a></p>\n<p>3. Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. <i>J Clin Pharmacol</i>. 2005;45(1):68-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15601807\">[PubMed 15601807]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8529":"<p><b>Title</b> LamoTRIgine / Atazanavir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Ritonavir): This interaction is unlikely to be clinically significant when lamotrigine is combined with unboosted atazanavir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atazanavir may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor lamotrigine concentrations closely and watch for evidence of decreased effectiveness when using lamotrigine with ritonavir-boosted atazanavir. Lamotrigine dose adjustment may be necessary to maintain adequate concentrations and effectiveness. Monitoring is also recommended when using lamotrigine with cobicistat-boosted atazanavir because the effect of cobicistat on lamotrigine pharmacokinetics is unknown. Concurrent use of lamotrigine with unboosted atazanavir (i.e., without concurrent ritonavir) is unlikely to result in any clinically significant interaction.</p> \n<p><b>Discussion</b> The AUC of lamotrigine was reduced by an average of 12% with concurrent atazanavir in a study of 21 healthy volunteers receiving lamotrigine 100 mg (single dose) in addition to atazanavir (400 mg once daily).<sup>1</sup> With concurrent use of atazanavir/ritonavir (300 mg/100 mg daily), the lamotrigine AUC was reduced by an average of 32%.<sup>1</sup> The precise clinical impact of this interaction in uncertain. The atazanavir prescribing information does caution that lamotrigine dose adjustment may be needed if used with ritonavir-boosted atazanavir, but that dose adjustments should not be needed with unboosted atazanavir.<sup>2</sup><br><br>The mechanism responsible for decreased lamotrigine exposure appears to be enhanced lamotrigine metabolism (via glucuronidation) caused by atazanavir and/or ritonavir. The greater effect seen with ritonavir-boosted atazanavir may reflect enhanced atazanavir concentrations/effects and/or combined induction of glucuronidation by both atazanavir and ritonavir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Burger DM, Huisman A, Van Ewijk N, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. <i>Clin Pharmacol Ther</i>. 2008;84(6):698-703. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18528434\">[PubMed 18528434]</a></p>\n<p>2. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8530":"<p><b>Title</b> Serotonin Modulators / Tedizolid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tedizolid may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for symptoms of serotonin toxicity/serotonin syndrome (eg, mental status changes, autonomic instability, neuromuscular hyperactivity) when tedizolid is combined with a serotonin modulator.</p>\n<div>\n <p><b>Serotonin Modulators Interacting Members</b> 5-Hydroxytryptophan, Almotriptan, Amitriptyline, Amoxapine, Bromocriptine, BusPIRone, Cabergoline, Citalopram, ClomiPRAMINE, Cyclobenzaprine, Dapoxetine, Desipramine, Desvenlafaxine, Dextromethorphan, Dihydroergotamine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), DULoxetine, Eletriptan, Ergoloid Mesylates, Ergonovine, Ergotamine, Escitalopram, FentaNYL, FLUoxetine, FluvoxaMINE, Frovatriptan, Imipramine, Isocarboxazid, Levomilnacipran, Linezolid, Lithium, Lofepramine, Lorcaserin, Maprotiline, Melitracen [INT], Meperidine, Methadone, Methylene Blue, Methylergonovine, Milnacipran, Mirtazapine, Moclobemide, Naratriptan, Nefazodone, Nortriptyline, PARoxetine, Pergolide, Phenelzine, Procarbazine, Promethazine, Protriptyline, Rasagiline, Rizatriptan, Safinamide, SAMe (S-adenosylmethionine), Selegiline, Sertraline, St John's Wort, SUMAtriptan, Tapentadol, Tedizolid, TraMADol, Tranylcypromine, TraZODone, Trimipramine, Tryptophan, Venlafaxine, Vilazodone, Vortioxetine, ZOLMitriptan<br><b>Exception</b> Nicergoline</p>\n</div> \n<p><b>Discussion</b> The clinical effects of the combination of tedizolid and a serotonin modulator have not been evaluated, as patients taking serotonin modulators were excluded from all tedizolid phase 3 clinical trials.<sup>1</sup> <br><br>Tedizolid is a reversible, nonselective inhibitor of both monoamine oxidase (MAO)-A and MAO-B in vitro.<sup>2</sup> Thus, the potential for serotonin toxicity/serotonin syndrome (SS/ST) exists if combined with other serotonin modulating agents. The only study evaluating the serotonergic potential of tedizolid was conducted in mice.<sup>2</sup> A head twitch response protocol, a surrogate measure of in vivo serotonin receptor 2A activation, was assessed in adult mice. Activation of the serotonin receptor 2A subtype is thought to contribute to the development of SS/ST.<sup>3</sup> The mice were treated with placebo, human equivalent therapeutic exposures of linezolid, fluoxetine, and moclobemide, and increasing concentrations of tedizolid (1x, 3x, 10x, and 30x the human equivalent therapeutic exposure). After each treatment, 5-hydroxy-DL-tryptophan (the precursor to serotonin) was administered. Significantly more head twitches were observed with linezolid, fluoxetine, and moclobemide compared to placebo. Tedizolid treated mice, even at concentrations 30x the expected human exposure, showed no increase in head twitches compared to placebo.<sup>2</sup> <br><br>Linezolid, another oxazolidinone antibiotic with MAO inhibitory properties, has been implicated in the development of SS/ST when combined with other serotonin modulators. <sup>4,5,6,7,8</sup> Compared to linezolid, tedizolid has a slightly stronger affinity and inhibitory effect on MAO-A, with a similar effect on MAO-B. However, at therapeutic doses, maximum serum concentrations of linezolid are approximately 10-fold greater than tedizolid. Thus, the predicted in vivo inhibition of both MAO enzymes is expected to be less with tedizolid compared with linezolid.<sup>2</sup> This may explain the difference in head twitch response seen between these agents.<br><br>Due to the severity of SS/ST, if tedizolid is combined with a serotonin modulator, careful monitoring is likely warranted until more data (either clinical trials or post-marketing reports) are available to further describe this potential interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sivextro</i> (tedizolid phosphate) [prescribing information]. Lexington, MA: Cubist Pharmaceuticals US; June 2014.</p>\n<p>2. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. <i>Antimicrob Agents Chemother</i>. 2013;57(7):3060-3066. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23612197\">[PubMed 23612197]</a></p>\n<p>3. Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15784664\">[PubMed 15784664]</a></p>\n<p>4. Lavery S, Ravi H, McDaniel WW, et al. Linezolid and serotonin syndrome. <i>Psychosomatics</i>. 2001;42(5):432-434. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11739912\">[PubMed 11739912]</a></p>\n<p>5. Wigen CL, Goetz MB. Serotonin syndrome and linezolid. <i>Clin Infect Dis</i>. 2002;34(12):1651-1652. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12032904\">[PubMed 12032904]</a></p>\n<p>6. DeBellis RJ, Schaefer OP, Liquori M, et al. Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient. <i>J Intensive Care Med</i>. 2005;20(6):351-353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16280409\">[PubMed 16280409]</a></p>\n<p>7. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. <i>Pharmacotherapy</i>. 2006;26(2):269-276. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16466332\">[PubMed 16466332]</a></p>\n<p>8. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. <i>Clin Infect Dis</i>. 2006;42(11):1578-1583. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16652315\">[PubMed 16652315]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8531":"<p><b>Title</b> Sympathomimetics / Tedizolid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tedizolid may enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased sympathomimetic effects (eg, blood pressure, heart rate, chest pain, etc.) if used in combination with tedizolid</p>\n<div>\n <p><b>Sympathomimetics Interacting Members</b> Acebrophylline, Albuterol, Amezinium, Aminophylline, Amphetamine, Arformoterol, Armodafinil, Bambuterol, Benzphetamine, Bitter Orange, Caffeine, Cocaine (Topical), Dexmethylphenidate, Dextroamphetamine, Diethylpropion, DOBUTamine, DOPamine, Doxapram, Dyphylline, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Fenoterol, Formoterol, Indacaterol, Isometheptene, Isoproterenol, Kola Nut, Levalbuterol, Levonordefrin, Lisdexamfetamine, Metaproterenol, Metaraminol, Methamphetamine, Methylphenidate, Midodrine, Modafinil, Naphazoline (Nasal), Naphazoline (Ophthalmic), Norepinephrine, Olodaterol, Oxymetazoline (Nasal), Phendimetrazine, Phentermine, Phenylephrine (Nasal), Phenylephrine (Ophthalmic), Phenylephrine (Systemic), Phenylephrine (Topical), Pirbuterol, Propylhexedrine, Pseudoephedrine, Ritodrine, Salmeterol, Terbutaline, Theophylline, Tulobuterol, Vilanterol, Xylometazoline</p>\n</div> \n<p><b>Discussion</b> In a randomized crossover study, 30 healthy participants received tedizolid (200 mg daily) or placebo for up to 14 days.<sup>1,2</sup> A washout period of 2 days was followed by the opposite intervention. On day 3 of each treatment period, participants received tyramine starting at 25 mg daily. An additional 50 mg of tyramine was added on each subsequent day (up to a maximum of 575 mg) until an increase in systolic blood pressure of 30 mm Hg or more was achieved. The mean tyramine dose needed to increase systolic blood pressure 30 mm Hg or more from baseline was 325 mg in tedizolid treated patients compared with 425 mg in placebo treated patients. Palpitations were reported more often in tedizolid treated patients compared with placebo (72.4% vs 46.4%).<sup>1,2</sup><br><br>In another randomized crossover study, 36 healthy participants received tedizolid (200 mg daily) or placebo for 5 days followed by pseudoephedrine (60 mg) on day 5.<sup>1,2</sup> A washout period of 2 days was followed by the opposite intervention. No differences in systolic blood pressure, diastolic blood pressure, or heart rate were seen between tedizolid and placebo treated patients.<sup>1,2</sup> In contrast, coadministration of linezolid (600 mg twice daily for 3 days), another oxazolidinone antibiotic with monoamine oxidase (MAO) inhibitory properties, with pseudoephedrine (60 mg twice, 4 hours apart) or phenylpropanolamine (25 mg twice, 4 hours apart) in healthy volunteers increased the maximum blood pressure elevating effect of those agents by an average of 14 mmHg and 24 mmHg, respectively.<sup>3,4</sup><br><br>Tedizolid is a reversible, nonselective inhibitor of both MAO-A and MAO-B in vitro.<sup>2</sup> Compared to linezolid, tedizolid has a slightly stronger affinity and inhibitory effect on MAO-A, with a similar effect on MAO-B. However, at therapeutic doses, maximum serum concentrations of linezolid are approximately 10-fold greater than tedizolid. Thus, the predicted in vivo inhibition of both MAO enzymes is expected to be less with tedizolid compared with linezolid.<sup>2</sup> This may explain the differences seen in blood pressure effects when these agents were combined with pseudoephedrine. <br><br>Administration of MAO inhibitors can lead to accumulation of norepinephrine, particularly within adrenergic neurons. The administration of a sympathomimetic agent can directly potentiate or cause the release of the stored excess norepinephrine, resulting in an exaggerated constriction of blood vessels and an increase in blood pressure. Although no changes in the blood pressure effects of pseudoephedrine were observed when combined with tedizolid, an increase in blood pressure sensitivity to tyramine was seen. Monitor patients for increased sympathomimetic effects if tedizolid is combined with a sympathomimetic agent. The magnitude of this interaction is expected to be less than what has been observed with the combination of linezolid and sympathomimetic agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sivextro</i> (tedizolid phosphate) [prescribing information]. Lexington, MA: Cubist Pharmaceuticals US; June 2014.</p>\n<p>2. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. <i>Antimicrob Agents Chemother</i>. 2013;57(7):3060-3066. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23612197\">[PubMed 23612197]</a></p>\n<p>3. <i> Zyvox</i> (linezolid) [prescribing information]. New York, NY: Pfizer Inc; September 2013.</p>\n<p>4. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. <i>J Clin Pharmacol</i>. 2001;41(5):563-572. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11361053\">[PubMed 11361053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8532":"<p><b>Title</b> QuiNIDine / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of QuiNIDine. QuiNIDine may increase the serum concentration of FluvoxaMINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased concentrations and/or effects of both quinidine and fluvoxamine if these drugs are used together. Particular care should be used when starting concurrent use or when increasing the dose of either drug.</p> \n<p><b>Discussion</b> The maximum serum concentration of quinidine was an average of 35% higher with concurrent fluvoxamine in a study of healthy volunteers (N=6) who were given a single oral dose of quinidine (200 mg) on the fifth day of fluvoxamine (100 mg/day) administration.<sup>1</sup> The precise clinical significance of this interaction is uncertain.<br><br>The fluvoxamine prescribing information also recommends caution with concurrent use of strong CYP2D6 inhibitors such as quinidine due to a potential for quinidine to increase fluvoxamine concentrations.<sup>2</sup> Although specific data regarding this combination are not included, the fluvoxamine Cmax and AUC were 52% and 200% higher, respectively, in CYP2D6 poor metabolizers (i.e., genetically lacking functional CYP2D6) than in CYP2D6 extensive metabolizers, suggesting a possible similar difference in patients using strong CYP2D6 inhibitors.<sup>2</sup><br><br>At least two distinct mechanisms contribute to the potential interaction between fluvoxamine and quinidine. Fluvoxamine appears to inhibit the metabolism of quinidine, leading to increased quinidine concentrations. More specifically, the 3-hydroxylation and N-oxidation of quinidine appear to be subject to inhibition by fluvoxamine (inhibited by 43.5% and 33.3%, respectively), reflecting fluvoxamine inhibition of CYP3A and possibly CYP1A2 and/or CYP2C19.<sup>1</sup> Additionally, it is expected that quinidine would inhibit the CYP2D6-mediated metabolism of fluvoxamine, resulting in increased fluvoxamine concentrations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Damkier P, Hansen LL, Brosen K. Effect of fluvoxamine on the pharmacokinetics of quinidine. <i>Eur J Clin Pharmacol</i>. 1999;55(6):451-456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10492058\">[PubMed 10492058]</a></p>\n<p>2. <i>Luvox CR</i> (fluvoxamine) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; October 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8533":"<p><b>Title</b> Fluconazole / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> A: No known interaction</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists do not appear to affect serum concentration of Fluconazole. <b>Severity</b> N/A <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> In a study of 24 healthy volunteers, administration of intravenous cimetidine (300 mg x 2 doses, with additional 100 mg doses to maintain gastric pH greater than 6.0) followed by oral fluconazole (200 mg) resulted in no change in the AUC, maximum serum concentration (Cmax), or time to reach maximum serum concentration (Tmax) of fluconazole.<sup>1</sup>. In another report, fluconazole pharmacokinetics were unaffected when oral fluconazole (100 mg) was administered following treatment with oral famotidine (40 mg x 2 doses) in 12 healthy participants.<sup>2</sup> In a study described in the fluconazole prescribing information, administration of a single dose of oral cimetidine (400 mg) followed by a single dose of oral fluconazole (100 mg) to 6 healthy volunteers resulted in a decrease in the fluconazole AUC and Cmax by 13% and 19%, respectively.<sup>3</sup> This lack of interaction is in contrast to ketoconazole and itraconazole, where administration of H2- receptor antagonists and the presence of a less acidic gastric environment significantly impair absorption.<sup>1,2,4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. <i>Ann Intern Med</i>. 1991;114(9):755-757. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2012358\">[PubMed 2012358]</a></p>\n<p>2. Lim SG, Sawyerr AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. <i>Aliment Pharmacol Ther</i>. 1993;7(3):317-321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8117350\">[PubMed 8117350]</a></p>\n<p>3. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2014.</p>\n<p>4. Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. <i>Antimicrob Agents Chemother</i>. 1991;35(9):1765-1771. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1952845\">[PubMed 1952845]</a></p>\n<p>5. Van Der Meer JW, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. <i>J Antimicrob Chemother</i>. 1980;6(4):552-554. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6253434\">[PubMed 6253434]</a></p>\n<p>6. Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. <i>Hematol Oncol</i>. 1998;16(1):33-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9821410\">[PubMed 9821410]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8534":"<p><b>Title</b> Apremilast / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Apremilast. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The apremilast AUC and maximum serum concentration (Cmax) were increased by an average of 36% and 5%, respectively, when ketoconazole was administered with a single dose of apremilast 20 mg.<sup>1</sup> The clinical significance of such a modest increase in apremilast exposure is uncertain but expected to be minor.<br><br>The likely mechanism of this interaction is decreased CYP3A-mediated metabolism of apremilast due to the CYP3A4 inhibiting effect of ketoconazole.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu Y, Zhou S, Wan Y, Wu A, Palmisano M. The impact of co-administration of ketoconazole and rifampin on the pharmacokinetics of apremilast in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2014; Jun 24 (Epub ahead of print). doi: 10.1111/bcp.12448. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24962564\">[PubMed 24962564]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8535":"<p><b>Title</b> Thalidomide / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients using this combination closely for signs and symptoms of thromboembolism such as swelling, redness, warmth, or pain in the legs, dyspnea, tachypnea, hemoptysis, or chest pain. Advise patients of potential risks and encourage prompt reporting of any thromboembolism signs or symptoms.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> Thalidomide prescribing information warns of a possible increase in the risk for thromboembolism with concomitant use of drugs that may independently increase the risk for thromboembolism, such as erythropoiesis-stimulating agents or estrogen-containing therapies, though specific data regarding the actual risks with such combinations are lacking.<sup>1</sup> The use of thalidomide itself is associated with a significant risk for thromboembolism; as described in the prescribing information, 22% of those treated with thalidomide plus dexamethasone experienced thromboembolism versus 5% of those treated with dexamethasone alone in a study of patients with multiple myeloma.<sup>1</sup><br><br>The proposed mechanism of interaction is an additive thromboembolism risk with concomitant administration.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Thalidomid</i> (thalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8538":"<p><b>Title</b> Lercanidipine / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lercanidipine may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Lercanidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of lercanidipine and cyclosporine. Australia and UK product labeling specifically lists this combination as contraindicated.</p> \n<p><b>Discussion</b> In a clinical study summarized in lercanidipine Australia and UK summaries of product characteristics, simultaneous coadministration of lercanidipine with cyclosporine increased the AUC of lercanidipine by 3 fold and increased cyclosporine bioavailability by 21%.<sup>1,2</sup> Administration of cyclosporine 3 hours after lercanidipine increased the bioavailability of cyclosporine by 27% but had no impact on lercanidipine AUC.<br><br>The suspected primary mechanism of this interaction is cyclosporine inhibition of CYP3A4 mediated lercanidipine metabolism. The mechanism by which lercanidipine may increase cyclosporine bioavailability is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zircol</i> (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013.</p>\n<p>2. Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8539":"<p><b>Title</b> Metoprolol / Lercanidipine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Lercanidipine may enhance the hypotensive effect of Metoprolol. Metoprolol may decrease the serum concentration of Lercanidipine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced lercanidipine effects in patients receiving metoprolol, and increase lercanidipine dose as clinically indicated. Some shared effects of these agents (e.g., reductions in blood pressure) may be enhanced during coadministration despite reductions in lercanidipine exposure.</p> \n<p><b>Discussion</b> In a clinical study summarized in lercanidipine UK and Australia summaries of product characteristics, coadministration with metoprolol decreased lercanidipine bioavailability by 50%.<sup>1</sup> The mechanism of this interaction is unclear. Product labeling suggests that this interaction may result from a decrease in hepatic blood flow during metoprolol treatment.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zircol</i> (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013.</p>\n<p>2. Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8540":"<p><b>Title</b> PredniSONE / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of PredniSONE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased steroid-related adverse effects if prednisone is combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a study of 4 healthy volunteers, administration of ketoconazole (200 mg daily for 6 days) resulted in no significant changes in the pharmacokinetics of prednisolone (the measured active metabolite) when administered with 20 mg oral prednisone.<sup>1</sup> Administration of intravenous prednisolone (20 mg single dose) following treatment with ketoconazole (200 mg daily for 6 days) also resulted in no change to prednisolone pharmacokinetic parameters in 6 healthy participants.<sup>2</sup> Another study of 14 healthy volunteers reported no change in prednisolone pharmacokinetics with the coadministration of prednisone (60 mg single dose) after itraconazole treatment (400 mg on day 1, 200 mg daily on days 2 through 4).<sup>3</sup> The absence of effect on prednisolone pharmacokinetics has also been reported with troleandomycin,<sup>4</sup> clarithromycin,<sup>5</sup> and grapefruit juice.<sup>6</sup><br><br>In contrast, in a study of 10 healthy subjects, administration of ritonavir (200 mg twice daily x 14.5 days) significantly increased prednisolone AUC following single 20 mg prednisone doses given on day 4 (37% increase) and day 14 (28% increase).<sup>7</sup> The AUC of prednisolone increased approximately 21%, 24%, and 47%, when prednisone or prednisolone was combined with diltiazem, itraconazole, and ketoconazole, respectively.<sup>8,9,10</sup> One brief letter describes the development of mania in a patient treated with prednisone 40 mg and clarithromycin 1000 mg daily.<sup>11</sup> The authors presume the reaction is a result of increased prednisone concentrations due to decreased metabolism caused by clarithromycin, though neurotoxicity has been reported as an adverse reaction to clarithromycin.<sup>12</sup><br><br>The mechanism of this potential interaction is likely CYP3A4 inhibition resulting in reduced prednisolone metabolism. The small pharmacokinetic changes and conflicting results from various pharmacokinetic studies likely reflect the minor reliance of prednisolone on CYP3A4 for metabolic elimination and the strength of the CYP3A4 inhibitor. The magnitude of the interaction between strong CYP3A4 inhibitors and prednisone is markedly less than with methylprednisolone, a steroid that relies heavily on CYP3A4 for elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ludwig EA, Slaughter RL, Savliwala M, Brass C, Jusko WJ. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. <i>DICP</i>. 1989;23(11):858-861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2596127\">[PubMed 2596127]</a></p>\n<p>2. Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. <i>Clin Pharmacol Ther</i>. 1991;49(5):558-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827622\">[PubMed 1827622]</a></p>\n<p>3. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. <i>Br J Clin Pharmacol</i>. 2001;51(5):443-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422002\">[PubMed 11422002]</a></p>\n<p>4. Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. <i>J Allergy Clin Immunol</i>. 1982;69(5):455-460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6978898\">[PubMed 6978898]</a></p>\n<p>5. Fost DA, Leung DY, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. <i>J Allergy Clin Immunol</i>. 1999;103(6):1031-1035. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10359882\">[PubMed 10359882]</a></p>\n<p>6. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. <i>Clin Pharmacol Ther</i>. 1995;57(3):318-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7697949\">[PubMed 7697949]</a></p>\n<p>7. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. <i>J Acquir Immune Defic Syndr</i>. 2005;40(5):573-580. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16284534\">[PubMed 16284534]</a></p>\n<p>8. Imani S, Jusko W, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. <i>Pediatr Transplant</i>. 1999;3(2):126-130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10389134\">[PubMed 10389134]</a></p>\n<p>9. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. <i>Eur J Clin Pharmacol</i>. 2000;56(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10853878\">[PubMed 10853878]</a></p>\n<p>10. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. <i>Clin Pharmacol Ther</i>. 1999;45(4):366-372. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2639662\">[PubMed 2639662]</a></p>\n<p>11. Finkenbine R, Gill HS. Case of mania due to prednisone-clarithromycin interaction. <i>Can J Psychiatry</i>. 1997;42(7):778. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9307841\">[PubMed 9307841]</a></p>\n<p>12. Bandettini di Poggio M, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. <i>J Clin Neurosci</i>. 2011;18(3):313-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21269833\">[PubMed 21269833]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8541":"<p><b>Title</b> PrednisoLONE (Systemic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Monitor for increased steroid-related adverse effects if prednisolone is combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a study of 4 healthy volunteers, administration of ketoconazole (200 mg daily for 6 days) resulted in no significant changes in the pharmacokinetics of prednisolone (the measured active metabolite) when administered with 20 mg oral prednisone.<sup>1</sup> Administration of intravenous prednisolone (20 mg single dose) following treatment with ketoconazole (200 mg daily for 6 days) also resulted in no change to prednisolone pharmacokinetic parameters in 6 healthy participants.<sup>2</sup> Another study of 14 healthy volunteers reported no change in prednisolone pharmacokinetics with the coadministration of prednisone (60 mg single dose) after itraconazole treatment (400 mg on day 1, 200 mg daily on days 2 through 4).<sup>3</sup> The absence of effect on prednisolone pharmacokinetics has also been reported with troleandomycin,<sup>4</sup> clarithromycin,<sup>5</sup> and grapefruit juice.<sup>6</sup><br><br>In contrast, in a study of 10 healthy subjects, administration of ritonavir (200 mg twice daily x 14.5 days) significantly increased prednisolone AUC following single 20 mg prednisone doses given on day 4 (37% increase) and day 14 (28% increase).<sup>7</sup> The AUC of prednisolone increased approximately 21%, 24%, and 47%, when prednisone or prednisolone was combined with diltiazem, itraconazole, and ketoconazole, respectively.<sup>8,9,10</sup> One brief letter describes the development of mania in a patient treated with prednisone 40 mg and clarithromycin 1000 mg daily.<sup>11</sup> The authors presume the reaction is a result of increased prednisone concentrations due to decreased metabolism caused by clarithromycin, though neurotoxicity has been reported as an adverse reaction to clarithromycin.<sup>12</sup><br><br>The mechanism of this potential interaction is likely CYP3A4 inhibition resulting in reduced prednisolone metabolism. The conflicting results from various pharmacokinetic studies likely reflect the minor reliance of prednisolone on CYP3A4 for metabolic elimination and the strength of the CYP3A4 inhibitor. The magnitude of the interaction between strong CYP3A4 inhibitors and prednisolone is markedly less than with methylprednisolone, a steroid that relies heavily on CYP3A4 for elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ludwig EA, Slaughter RL, Savliwala M, Brass C, Jusko WJ. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. <i>DICP</i>. 1989;23(11):858-861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2596127\">[PubMed 2596127]</a></p>\n<p>2. Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. <i>Clin Pharmacol Ther</i>. 1991;49(5):558-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827622\">[PubMed 1827622]</a></p>\n<p>3. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. <i>Br J Clin Pharmacol</i>. 2001;51(5):443-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422002\">[PubMed 11422002]</a></p>\n<p>4. Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. <i>J Allergy Clin Immunol</i>. 1982;69(5):455-460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6978898\">[PubMed 6978898]</a></p>\n<p>5. Fost DA, Leung DY, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. <i>J Allergy Clin Immunol</i>. 1999;103(6):1031-1035. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10359882\">[PubMed 10359882]</a></p>\n<p>6. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. <i>Clin Pharmacol Ther</i>. 1995;57(3):318-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7697949\">[PubMed 7697949]</a></p>\n<p>7. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. <i>J Acquir Immune Defic Syndr</i>. 2005;40(5):573-580. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16284534\">[PubMed 16284534]</a></p>\n<p>8. Imani S, Jusko W, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. <i>Pediatr Transplant</i>. 1999;3(2):126-130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10389134\">[PubMed 10389134]</a></p>\n<p>9. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. <i>Eur J Clin Pharmacol</i>. 2000;56(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10853878\">[PubMed 10853878]</a></p>\n<p>10. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. <i>Clin Pharmacol Ther</i>. 1999;45(4):366-372. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2639662\">[PubMed 2639662]</a></p>\n<p>11. Finkenbine R, Gill HS. Case of mania due to prednisone-clarithromycin interaction. <i>Can J Psychiatry</i>. 1997;42(7):778. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9307841\">[PubMed 9307841]</a></p>\n<p>12. Bandettini di Poggio M, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. <i>J Clin Neurosci</i>. 2011;18(3):313-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21269833\">[PubMed 21269833]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8542":"<p><b>Title</b> Simvastatin / Lercanidipine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lercanidipine may increase the serum concentration of Simvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer lercanidipine in the morning and simvastatin in the evening in patients receiving these drugs in combination.</p> \n<p><b>Discussion</b> In a clinical study summarized in lercanidipine UK and Australia summaries of product characteristics, coadministration of lercanidipine with simvastatin increased simvastatin and simvastatin acid AUCs by 56% and 28%, respectively.<sup>1,2</sup> The mechanism of this interaction is unknown. While lercanidipine product labeling describes these effects as being unlikely clinically significant, it does recommend administration of lercanidipine in the morning and simvastatin in the evening to minimize potential effects.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zircol</i> (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013.</p>\n<p>2. Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8543":"<p><b>Title</b> Lercanidipine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the vasodilatory effect of Lercanidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of lercanidipine and alcohol, and advise patients to avoid this combination.</p> \n<p><b>Discussion</b> Lercanidipine UK and Australia summaries of product characteristics state that its coadministration with alcohol should be avoided because alcohol may potentiate lercanidipine vasodilatory effects.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zircol</i> (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013.</p>\n<p>2. Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8544":"<p><b>Title</b> Lercanidipine / Cimetidine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Monitoring for enhanced systemic effects of lercanidipine may be warranted in patients receiving cimetidine doses greater than 400 mg twice daily.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Lercanidipine. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required in patients receiving cimetidine doses of 400 mg twice daily or lower. Monitoring for enhanced systemic effects of lercanidipine may be warranted in patients receiving greater cimetidine doses.</p> \n<p><b>Discussion</b> In a clinical study summarized in lercanidipine Australia and UK summaries of product characteristics, coadministration of cimetidine (400 mg twice daily) increased the maximum concentration and AUC of lercanidipine by 11%.<sup>1,2</sup> <br><br>The suspected primary mechanism of this interaction is cimetidine inhibition of CYP3A4 mediated lercanidipine metabolism. While the pharmacokinetic changes described with cimetidine 400 mg taken twice daily are not represented as clinically significant in product labeling, caution is advised whenever lercanidipine is used with higher cimetidine doses.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zircol</i> (lercanidipine) [summary of product characteristics]. Millers Point NSW, Australia: Alphapharm Pty Limited; February 2013.</p>\n<p>2. Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8545":"<p><b>Title</b> PredniSONE / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of PredniSONE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased adverse effects of prednisone if fluconazole is initiated and monitor for symptoms of acute steroid withdrawal or Addisonian crisis (hypotension, hyponatremia, hyperkalemia) if fluconazole therapy is stopped.</p> \n<p><b>Discussion</b> A case report describes a 50 year old female with an orthotopic liver transplant receiving 10 mg of prednisone daily along with fluconazole (dose not stated) for fungal infection prophylaxis.<sup>1</sup> Six weeks after transplantation the patient developed a surgical site infection and wound dehiscence for which she received stress doses of glucocorticoids (doses and specific drugs not stated), as well as antibiotics, and surgical repair of her wound. Two weeks after returning to her maintenance dose of prednisone 10 mg daily, her fluconazole therapy was stopped. Five days later she developed symptoms of an Addisonian crisis (hypotension, hyperkalemia, and hyponatremia). Her symptoms resolved with administration of fludrocortisone and hydrocortisone and she was eventually tapered back to prednisone 10 mg daily. The authors theorized that the discontinuation of fluconazole, and thus the removal of fluconazole-mediated inhibition of CYP3A4 prednisone metabolism, resulted in acute steroid withdrawal and an Addisonian crisis in this patient.<sup>1</sup><br><br>Pharmacokinetic studies support a role of CYP3A4 in the metabolism of prednisone. In a study of 10 healthy subjects, administration of ritonavir (200 mg twice daily x 14.5 days) significantly increased prednisolone AUC following single 20 mg prednisone doses given on day 4 (37% increase) and day 14 (28% increase) .<sup>2</sup> The AUC of prednisolone increased approximately 21%, 24%, and 47%, when prednisone or prednisolone was combined with diltiazem, itraconazole, and ketoconazole, respectively.<sup>3,4,5</sup><br><br>In contrast, in a study of 4 healthy volunteers, administration of ketoconazole (200 mg daily for 6 days) resulted in no significant changes in the pharmacokinetics of prednisolone (the measured active metabolite) when administered with 20 mg oral prednisone.<sup>6</sup> Administration of intravenous prednisolone (20 mg single dose) following treatment with ketoconazole (200 mg daily for 6 days) also resulted in no change to prednisolone pharmacokinetic parameters in 6 healthy participants.<sup>7</sup> Another study of 14 healthy volunteers reported no change in prednisolone pharmacokinetics with the coadministration of prednisone (60 mg single dose) after itraconazole treatment (400 mg on day 1, 200 mg daily on days 2 through 4).<sup>8</sup> The absence of effect on prednisolone pharmacokinetics has also been reported with troleandomycin,<sup>9</sup> clarithromycin,<sup>10</sup> and grapefruit juice.<sup>11</sup><br><br>The small pharmacokinetic changes and conflicting results from various pharmacokinetic studies likely reflect the minor reliance of prednisolone on CYP3A4 for metabolic elimination and the strength of the CYP3A4 inhibitor. The magnitude of the interaction between CYP3A4 inhibitors (such as fluconazole) and prednisone is markedly less than with methylprednisolone, a steroid that relies heavily on CYP3A4 for elimination. Since the details of the stress doses of steroids the liver transplant patient received are unknown, it is unclear what role they may have played in a drug interaction and/or an Addisonian crisis.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tiao GM, Martin J, Weber FL, Cohen RM, Hanto DW. Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. <i>Clin Transplant</i>. 1999;13(1 pt 1):62-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10081637\">[PubMed 10081637]</a></p>\n<p>2. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. <i>J Acquir Immune Defic Syndr</i>. 2005;40(5):573-580. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16284534\">[PubMed 16284534]</a></p>\n<p>3. Imani S, Jusko W, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. <i>Pediatr Transplant</i>. 1999;3(2):126-130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10389134\">[PubMed 10389134]</a></p>\n<p>4. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. <i>Eur J Clin Pharmacol</i>. 2000;56(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10853878\">[PubMed 10853878]</a></p>\n<p>5. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. <i>Clin Pharmacol Ther</i>. 1999;45(4):366-372. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2639662\">[PubMed 2639662]</a></p>\n<p>6. Ludwig EA, Slaughter RL, Savliwala M, Brass C, Jusko WJ. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. <i>DICP</i>. 1989;23(11):858-861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2596127\">[PubMed 2596127]</a></p>\n<p>7. Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. <i>Clin Pharmacol Ther</i>. 1991;49(5):558-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827622\">[PubMed 1827622]</a></p>\n<p>8. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. <i>Br J Clin Pharmacol</i>. 2001;51(5):443-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422002\">[PubMed 11422002]</a></p>\n<p>9. Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. <i>J Allergy Clin Immunol</i>. 1982;69(5):455-460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6978898\">[PubMed 6978898]</a></p>\n<p>10. Fost DA, Leung DY, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. <i>J Allergy Clin Immunol</i>. 1999;103(6):1031-1035. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10359882\">[PubMed 10359882]</a></p>\n<p>11. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. <i>Clin Pharmacol Ther</i>. 1995;57(3):318-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7697949\">[PubMed 7697949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8546":"<p><b>Title</b> Lercanidipine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lercanidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of lercanidipine in combination with any strong CYP3A4 inhibitor. UK product labeling specifically lists such combinations as contraindicated.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the lercanidipine UK summary of product characteristics, coadministration of ketoconazole increased the maximum concentration and AUC of S-lercanidipine (the main active isomer) by 8 and 15 fold, respectively.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is ketoconazole inhibition of CYP3A4 mediated lercanidipine metabolism. The lercanidipine UK summary of product characteristics lists its combination with ketoconazole or any other strong CYP3A4 inhibitor as contraindicated.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8547":"<p><b>Title</b> Lercanidipine / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Lercanidipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of lercanidipine in combination with grapefruit juice, and advise patients to avoid this combination. Lercanidipine UK product labeling specifically lists its use with grapefruit juice as contraindicated.</p> \n<p><b>Discussion</b> The lercanidipine UK summary of product characteristics warns that its use in combination with grapefruit juice may increase systemic lercanidipine exposure and the risk of hypotension.<sup>1</sup> An interaction between these agents is expected based on the potential for grapefruit juice to inhibit CYP3A4, a major enzyme responsible for lercanidipine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lercanidipine [summary of product characteristics]. Devon, UK: Arrow Generics Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8548":"<p><b>Title</b> Corticosteroids (Systemic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased steroid-related adverse effects if a systemic corticosteroid is combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), Triamcinolone (Systemic)<br><b>Exceptions</b> MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE</p>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The AUC of both oral and intravenous methylprednisolone (48 mg or 16 mg single dose) increased 2.5- to 3.9-fold in 3 pharmacokinetic studies when administered following a 4-day course of itraconazole.<sup>1,2,3</sup> The AUC of intravenous methylprednisolone (20 mg) was increased 2.5-fold after a 6 day course of ketoconazole (200 mg daily),<sup>4</sup> and the dose of intravenous methylprednisolone had to be reduced approximately 60% when administered with ketoconazole (200 mg daily for 7 days) in order to maintain a similar AUC with methylprednisolone alone.<sup>5</sup> Increases in methylprednisolone exposure have also been observed in studies with nefazodone,<sup>6</sup> clarithromycin,<sup>7</sup> and the moderate CYP3A4 inhibitors diltiazem<sup>8,9</sup> and erythromycin.<sup>10</sup> When dexamethasone was combined with itraconazole (200 mg daily for 4 days), a 2.2-fold and 2.6-fold increase in dexamethasone AUC was observed with oral (4.5 mg) and intravenous (5 mg) dexamethasone, respectively.<sup>11</sup> A case report describes the development of steroid-related toxicity (myopathy and insulin resistance) after itraconazole initiation in a lung transplant patient taking methylprednisolone 12 mg daily that resolved after itraconazole discontinuation.<sup>12</sup><br><br>Smaller changes in steroid exposure have been observed with prednisone and prednisolone when combined with strong CYP3A4 inhibitors. In a study of 10 healthy subjects, administration of ritonavir (200 mg twice daily x 14.5 days) significantly increased prednisolone (the measured active metabolite) AUC following single 20 mg prednisone doses given on day 4 (37% increase) and day 14 (28% increase).<sup>13</sup> The AUC of prednisolone increased approximately 21%, 24%, and 47%, when prednisone or prednisolone was combined with diltiazem, itraconazole, and ketoconazole, respectively.<sup>14,15,16</sup> In contrast, in a study of 4 healthy volunteers, administration of ketoconazole (200 mg daily for 6 days) resulted in no significant changes in the pharmacokinetics of prednisolone when administered with 20 mg oral prednisone.<sup>17</sup> Administration of intravenous prednisolone (20 mg single dose) following treatment with ketoconazole (200 mg daily for 6 days) also resulted in no change to prednisolone pharmacokinetic parameters in 6 healthy participants.<sup>18</sup> Another study of 14 healthy volunteers reported no change in prednisolone pharmacokinetics with the coadministration of prednisone (60 mg single dose) after itraconazole treatment (400 mg on day 1, 200 mg daily on days 2 through 4).<sup>1</sup> The absence of effect on prednisolone pharmacokinetics has also been reported with troleandomycin,<sup>19</sup> clarithromycin,<sup>7</sup> and grapefruit juice.<sup>20</sup><br><br>Although no formal pharmacokinetic studies have been conducted, numerous case reports describe the development of exogenous Cushing syndrome and secondary adrenal insufficiency following triamcinolone injections (40-80 mg intramuscular, intra-articular, or epidural) given to ritonavir treated patients.<sup>21,22,23,24,25,26,27</sup> A case of Cushing syndrome was reported in a patient taking nefazodone who received intra-articular triamcinolone,<sup>28</sup> and a case of adrenal insufficiency was reported in a patient taking cobicistat who received interlaminar spinal injections of triamcinolone.<sup>29</sup> Unexpectedly high triamcinolone serum concentrations<sup>22,23,24,28</sup> and decreases in CD4 lymphocytes<sup>24,26,27</sup> were also reported in some cases.<br><br>The mechanism of these potential interactions is likely due to the inhibition of CYP3A4-mediated corticosteroid metabolism. Although it appears that most steroids undergo CYP3A4 mediated metabolism,<sup>30</sup> the extent to which each available corticosteroid relies on CYP3A4 for metabolism has not been fully described. It appears that the magnitude and consistency of the interaction is greater with corticosteroids that rely more heavily on CYP3A4 for metabolic elimination (eg methylprednisolone, dexamethasone).<sup>31</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. <i>Br J Clin Pharmacol</i>. 2001;51(5):443-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422002\">[PubMed 11422002]</a></p>\n<p>2. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. <i>Clin Pharmacol Ther</i>. 1998;64(4):363-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9797792\">[PubMed 9797792]</a></p>\n<p>3. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. <i>Pharmacol Toxicol</i>. 1999;85(1):29-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10426160\">[PubMed 10426160]</a></p>\n<p>4. Glynn AM, Slaughter RL, Brass C, D’Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. <i>Clin Pharmacol Ther</i>. 1986;39(6):654-659. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3709030\">[PubMed 3709030]</a></p>\n<p>5. Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ. Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol. <i>Clin Pharmacol Ther</i>. 1987;42(4):465-470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3311551\">[PubMed 3311551]</a></p>\n<p>6. Kotlyar M, Brewer ER, Golding M, Carson SW. Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect. <i>J Clin Psychopharmacol</i>. 2003;23(6):652-656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14624194\">[PubMed 14624194]</a></p>\n<p>7. Fost DA, Leung DY, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. <i>J Allergy Clin Immunol</i>. 1999;103(6):1031-1035. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10359882\">[PubMed 10359882]</a></p>\n<p>8. Varis T, Backman JT, Kivisto KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. <i>Clin Pharmacol Ther</i>. 2000;67(3):215-221. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10741623\">[PubMed 10741623]</a></p>\n<p>9. Booker BM, Magee MH, Blum RA, Lates CD, Jusko WJ. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. <i>Clin Pharmacol Ther</i>. 2002;72(4):370-382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12386639\">[PubMed 12386639]</a></p>\n<p>10. LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. <i>J Allergy Clin Immunol</i>. 1983;72(1):34-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6602160\">[PubMed 6602160]</a></p>\n<p>11. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. <i>Clin Pharmacol Ther</i>. 2000;68(5):487-494. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11103751\">[PubMed 11103751]</a></p>\n<p>12. Linthoudt H, Van Raemdonck D, Lerut T, Demedts M, Verleden G. The association of itraconazole and methylprednisolone may give rise to important steroid-related side effects. <i>J Heart Lung Transplant</i>. 1996;15(11):1165. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8956126\">[PubMed 8956126]</a></p>\n<p>13. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. <i>J Acquir Immune Defic Syndr</i>. 2005;40(5):573-580. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16284534\">[PubMed 16284534]</a></p>\n<p>14. Imani S, Jusko W, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. <i>Pediatr Transplant</i>. 1999;3(2):126-130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10389134\">[PubMed 10389134]</a></p>\n<p>15. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. <i>Eur J Clin Pharmacol</i>. 2000;56(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10853878\">[PubMed 10853878]</a></p>\n<p>16. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. <i>Clin Pharmacol Ther</i>. 1999;45(4):366-372. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2639662\">[PubMed 2639662]</a></p>\n<p>17. Ludwig EA, Slaughter RL, Savliwala M, Brass C, Jusko WJ. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. <i>DICP</i>. 1989;23(11):858-861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2596127\">[PubMed 2596127]</a></p>\n<p>18. Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. <i>Clin Pharmacol Ther</i>. 1991;49(5):558-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827622\">[PubMed 1827622]</a></p>\n<p>19. Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. <i>J Allergy Clin Immunol</i>. 1982;69(5):455-460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6978898\">[PubMed 6978898]</a></p>\n<p>20. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. <i>Clin Pharmacol Ther</i>. 1995;57(3):318-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7697949\">[PubMed 7697949]</a></p>\n<p>21. Levine D, Ananthakrishnan S, Garg A. Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy. <i>J Am Acad Dermatol</i>. 2011;65(4):877-878. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21920248\">[PubMed 21920248]</a></p>\n<p>22. Danaher PJ, Salsbury TL, Delmar JA. Metabolic derangement after injection of triamcinolone into the hip of an HIV-infected patient receiving ritonavir. <i>Orthopedics</i>. 2009;32(6):450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19634808\">[PubMed 19634808]</a></p>\n<p>23. Dort K, Padia S, Wispelwey B, Moore CC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. <i>AIDS Res Ther</i>. 2009;6:10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19505306\">[PubMed 19505306]</a></p>\n<p>24. Ramanathan R, Pau AK, Busse KH, et al. Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. <i>Clin Infect Dis</i>. 2008;47(12):e97-e99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18991509\">[PubMed 18991509]</a></p>\n<p>25. Yombi JC, Maiter D, Belkhir L, Nzeusseu A, Vandercam B. Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. <i>Clin Rheumatol</i>. 2008;27(suppl 2):S79-S82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18827959\">[PubMed 18827959]</a></p>\n<p>26. Albert NE, Kazi S, Santoro J, Dougherty R. Ritonavir and epidural triamcinolone as a cause of iatrogenic Cushing's syndrome. <i>Am J Med Sci</i>. 2012;344(1):72-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22543594\">[PubMed 22543594]</a></p>\n<p>27. Grierson MJ, Harrast MA. Iatrogenic Cushing syndrome after epidural steroid injections for lumbar radiculopathy in an HIV-infected patient treated with ritonavir: a case report highlighting drug interactions for spine interventionalists. <i>PM R</i>. 2012;4(3):234-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22443962\">[PubMed 22443962]</a></p>\n<p>28. Hagan JB, Erickson D, Singh RJ. Triamcinolone acetonide induced secondary adrenal insufficiency related to impaired CYP3A4 metabolism by coadministration of nefazodone. <i>Pain Med</i>. 2010;11(7):1132-1135. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20456080\">[PubMed 20456080]</a></p>\n<p>29. Wassner C, Maiti S, Kodroff K, Cohen H. Iatrogenic adrenal insufficiency secondary to combination therapy with elvitegravir/cobicistat/tenofovir disproxil fumarate/emtricitabine and interlaminar triamcinolone injection in an AIDS patient. <i>J Int Assoc Provid AIDS Care</i>. 2017;16(6):535-539. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28895486\">[PubMed 28895486]</a></p>\n<p>30. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. <i>Arch Biochem Biophys</i>. 1988;263(2):424-436. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3259858\">[PubMed 3259858]</a></p>\n<p>31. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. <i>J Pharmacol Exp Ther</i>. 1996;277(1):105-112. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8613906\">[PubMed 8613906]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8549":"<p><b>Title</b> Ulipristal / Bosentan</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bosentan may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with bosentan. Concurrent use may result in impaired ulipristal clinical effectiveness.</p> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup> US labeling also recommends against its use in combination with several other drugs with the potential to induce CYP3A4 (e.g., bosentan, felbamate, griseofulvin, topiramate).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8550":"<p><b>Title</b> Ulipristal / Felbamate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Felbamate may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with felbamate. Concurrent use may result in impaired ulipristal clinical effectiveness.</p> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup> US labeling also recommends against its use in combination with several other drugs with the potential to induce CYP3A4 (e.g., bosentan, felbamate, griseofulvin, topiramate).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8551":"<p><b>Title</b> Ulipristal / Griseofulvin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Griseofulvin may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with griseofulvin. Concurrent use may result in impaired ulipristal clinical effectiveness.</p> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup> US labeling also recommends against its use in combination with several other drugs with the potential to induce CYP3A4 (e.g., bosentan, felbamate, griseofulvin, topiramate).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8552":"<p><b>Title</b> Ulipristal / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with St. John's wort. Concurrent use may result in impaired ulipristal clinical effectiveness.</p> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer (including St. John's wort, which may strongly induce CYP3A4 under some circumstances).<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8553":"<p><b>Title</b> Ulipristal / Topiramate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Topiramate may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with topiramate. Concurrent use may result in impaired ulipristal clinical effectiveness.</p> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup> US labeling also recommends against its use in combination with several other drugs with the potential to induce CYP3A4 (e.g., bosentan, felbamate, griseofulvin, topiramate).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8554":"<p><b>Title</b> Ulipristal / Efavirenz</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Efavirenz may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with efavirenz. Concurrent use may result in impaired ulipristal clinical effectiveness.</p> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup> US labeling also recommends against its use in combination with several other drugs with the potential to induce CYP3A4 (e.g., bosentan, felbamate, griseofulvin, topiramate).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8555":"<p><b>Title</b> Ulipristal / Barbiturates</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Barbiturates may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with any barbiturate. Concurrent use may result in impaired ulipristal clinical effectiveness.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup> Barbiturates are also included among CYP3A4 inducing drugs to avoid (note that some but not all are established strong CYP3A4 inducers).</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8556":"<p><b>Title</b> Lithium / Caffeine and Caffeine Containing Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Caffeine and Caffeine Containing Products may decrease the serum concentration of Lithium. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced lithium serum concentrations/effects in patients who substantially increase caffeine consumption, or for increased lithium serum concentrations/effects in patients who substantially decrease or stop caffeine consumption.</p>\n<div>\n <p><b>Caffeine and Caffeine Containing Products Interacting Members</b> Caffeine, Kola Nut</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 11 patients reporting heavy caffeine consumption (4 or more cups of coffee daily), abstinence from caffeine for 2 weeks was associated with an approximate 24% average increase in lithium serum concentrations.<sup>1</sup> Subsequent caffeine resumption was associated with a return to baseline (before caffeine abstinence) lithium concentrations. Published case reports also describe apparent increases in lithium effects (specifically tremor) following caffeine discontinuation, or decreased lithium concentrations/effects during periods of heavy caffeine consumption.<sup>2,3</sup><br><br>The exact mechanism of this interaction is unknown. Caffeine likely increases lithium renal clearance and fractional excretion.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mester R, Toren P, Mizrachi I, Wolmer L, Karni N, Weizman A. Caffeine withdrawal increases lithium blood levels. <i>Biol Psychiatry</i>. 1995;37(5):348-350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7748990\">[PubMed 7748990]</a></p>\n<p>2. Jefferson JW. Lithium tremor and caffeine intake: two cases of drinking less and shaking more. <i>J Clin Psychiatry</i>. 1988;49(2):72-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3338980\">[PubMed 3338980]</a></p>\n<p>3. Kralovec K, Fartacek R, Ploderl M, Fartacek C, Aichhorn W. Low serum lithium associated with immoderate use of Coca-Cola Zero. <i>J Clin Psychopharmacol</i>. 2011;31(4):543-544. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21720234\">[PubMed 21720234]</a></p>\n<p>4. Shirley DG, Walter SJ, Noormohamed FH. Natriuretic effect of caffeine: assessment of segmental sodium reabsorption in humans. <i>Clin Sci (Lond)</i>. 2002;103(5):461-466. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12401118\">[PubMed 12401118]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8557":"<p><b>Title</b> Bacitracin (Systemic) / Streptomycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Streptomycin may enhance the nephrotoxic effect of Bacitracin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of systemic bacitracin and streptomycin.</p> \n<p><b>Discussion</b> Bacitracin US prescribing information specifically recommends that its use in combination with certain nephrotoxic antibiotics (specifically, colistin, kanamycin, neomycin, streptomycin, and polymyxin B) should be avoided due to the potential for enhanced renal toxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacitracin [prescribing information]. New York, NY: Pfizer Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8558":"<p><b>Title</b> Bacitracin (Systemic) / Kanamycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Kanamycin may enhance the nephrotoxic effect of Bacitracin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of systemic bacitracin and kanamycin.</p> \n<p><b>Discussion</b> Bacitracin US prescribing information specifically recommends that its use in combination with certain nephrotoxic antibiotics (specifically, colistin, kanamycin, neomycin, streptomycin, and polymyxin B) should be avoided due to the potential for enhanced renal toxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacitracin [prescribing information]. New York, NY: Pfizer Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8559":"<p><b>Title</b> Bacitracin (Systemic) / Polymyxin B</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction is only anticipated with polymyxin B uses that are potentially nephrotoxic due to substantial systemic exposure (e.g, intravenous or intramuscular use).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Polymyxin B may enhance the nephrotoxic effect of Bacitracin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of systemic bacitracin and polymyxin B.</p> \n<p><b>Discussion</b> Bacitracin US prescribing information specifically recommends that its use in combination with certain nephrotoxic antibiotics (specifically, colistin, kanamycin, neomycin, streptomycin, and polymyxin B) should be avoided due to the potential for enhanced renal toxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacitracin [prescribing information]. New York, NY: Pfizer Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8560":"<p><b>Title</b> Bacitracin (Systemic) / Colistimethate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Colistimethate may enhance the nephrotoxic effect of Bacitracin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of systemic bacitracin and colistimethate.</p> \n<p><b>Discussion</b> Bacitracin US prescribing information specifically recommends that its use in combination with certain nephrotoxic antibiotics (specifically, colistin, kanamycin, neomycin, streptomycin, and polymyxin B) should be avoided due to the potential for enhanced renal toxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacitracin [prescribing information]. New York, NY: Pfizer Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8561":"<p><b>Title</b> Bacitracin (Systemic) / Neomycin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Neomycin may enhance the nephrotoxic effect of Bacitracin (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of systemic bacitracin and neomycin.</p> \n<p><b>Discussion</b> Bacitracin US prescribing information specifically recommends that its use in combination with certain nephrotoxic antibiotics (specifically, colistin, kanamycin, neomycin, streptomycin, and polymyxin B) should be avoided due to the potential for enhanced renal toxicity.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bacitracin [prescribing information]. New York, NY: Pfizer Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8562":"<p><b>Title</b> Inhalational Anesthetics / Ephedra</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ephedra may enhance the arrhythmogenic effect of Inhalational Anesthetics. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of ephedra in patients receiving inhalational anesthetic agents.</p>\n<div>\n <p><b>Inhalational Anesthetics Interacting Members</b> Desflurane, Halothane, Isoflurane, Sevoflurane</p>\n</div> \n<p><b>Discussion</b> Prescribing information for ephedrine ( a major active constituent of ephedra) warns that inhalational anesthetics such as halothane may sensitize the heart to arrhythmic actions of sympathomimetic drugs such as ephedrine.<sup>1</sup><br><br>A study in dogs demonstrated induction of arrhythmias including premature ventricular contractions (PVCs), second grade atrioventricular block, and sinus tachycardia in all (7/7) dogs receiving a single dose of ephedrine 0.5 mg/kg under halothane anesthesia.<sup>2</sup> A second study in dogs showed induction of arrhythmias in approximately half of all dogs infused with ephedrine at a rate of 250 mcg/kg/hr or 1 mg/kg/hr under anesthesia with halothane or isoflurane, with no significant difference between anesthetic agents.<sup>3</sup><br><br>Data in humans are limited. One study of risk factors for arrhythmia during esophagectomy under sevoflurane / isoflurane anesthesia found that greater doses of ephedrine were associated with development of arrhythmia.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ephedrine sulfate [prescribing information]. West Columbia, SC: Parenta Pharmaceuticals, Inc; February 2005.</p>\n<p>2. Takaori M, Loehning RW. Ventricular arrhythmias during halothane anaesthesia: effect of isoproterenol, aminophylline, and ephedrine. <i>Can Anaesth Soc J</i>. 1965; 12:275-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14294788\">[PubMed 14294788]</a></p>\n<p>3. Tucker WK, Rackstein AD, Munson ES. Comparison of arrhythmic doses of adrenaline, metaraminol, ephedrine and phenylephrine during isoflurane and halothant anaesthesia in dogs. <i>Br J Anaesth</i>. 1974;46(6):392-396. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4458752\">[PubMed 4458752]</a></p>\n<p>4. Hahm TS, Lee JJ, Yang MK, Kim JA. Risk factors for an intraoperative arrhythmia during esophagectomy. <i>Yonsei Med J</i>. 2007;48(3):474-479. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17594156\">[PubMed 17594156]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8563":"<p><b>Title</b> Droxidopa / Ephedra</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ephedra may enhance the hypertensive effect of Droxidopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of droxidopa with drugs that increase blood pressure (such as ephedrine, a major active constituent of ephedra) is expected to result in an increased risk for supine hypertension. Closely monitor patient blood pressure (including in supine and head-elevated positions) and for any evidence of toxicity. Follow other recommendations to manage this risk, such as having patients elevate the heads of their beds while sleeping or resting.</p> \n<p><b>Discussion</b> According to the prescribing information for droxidopa, its use is associated with a risk for supine hypertension, and it is expected that concurrent use of other drugs that can elevate blood pressure would increase this risk.<sup>1</sup> During clinical trials, droxidopa therapy (for 8-10 weeks) was associated with an increased incidence of hypertension compared to placebo (7% vs 0.9%), but specific data regarding the incidence of supine hypertension are not provided.<sup>1</sup><br><br>The mechanism for this interaction is likely additive pressor effects of droxidopa, which is converted in vivo to norepinephrine, together with other drugs that can increase blood pressure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Northera</i> (droxidopa) [prescribing information]. Charlotte, NC: Chelsea Therapeutics, Inc; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8564":"<p><b>Title</b> Anticholinergic Agents / Acetylcholinesterase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for reduced therapeutic effect of acetylcholinesterase inhibitors if combined with an anticholinergic agent. Any desired anticholinergic effects may also be reduced in the presence of an acetylcholinesterase inhibitor.</p>\n<div>\n <p><b>Acetylcholinesterase Inhibitors Interacting Members</b> Distigmine, Donepezil, Edrophonium, Galantamine, Neostigmine, Physostigmine, Pyridostigmine, Rivastigmine</p>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The effects of anticholinergics and acetylcholinesterase inhibitors oppose each other (one blocks the effects of acetylcholine while the other prevents the breakdown of acetylcholine), which may result in a diminished therapeutic effect. Several acetylcholinesterase inhibitor product labels acknowledge the opposing pharmacology of these agents<sup>1,2,3</sup> and recommend the avoidance of the combination if possible.<sup>3</sup> Of note, atropine is the recommended antidote for excessive cholinergic effects for many of these agents.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aricept</i> (donepezil) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2013.</p>\n<p>2. <i>Razadyne</i> (galantamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; June 2013. </p>\n<p>3. <i>Exelon</i> (rivastigmine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2013. </p>\n<p>4. <i>Bloxiverz</i> (neostigmine methylsulfate) [prescribing information]. Chesterfield, MO: Eclat Pharmaceuticals; May 2013. </p>\n<p>5. <i>Mestinon</i> (pyridostigmine) [prescribing information]. Costa Mesa, CA: ICN Pharmaceuticals Inc; July 2001.</p>\n<p>6. <i>Enlon</i> (edrophonium) [prescribing information]. Lake Forest, IL: Bioniche Pharma USA LLC; March 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8565":"<p><b>Title</b> Acetaminophen / Opioid Analgesics</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Opioid Analgesics may decrease the absorption of Acetaminophen. The extent to which this decreases total systemic exposure to acetaminophen is uncertain. <b>Severity</b> Minor <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Opioid Analgesics Interacting Members</b> Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, FentaNYL, Heroin, HYDROcodone, HYDROmorphone, Levorphanol, Meperidine, Meptazinol, Methadone, Morphine (Liposomal), Morphine (Systemic), Nalbuphine, Opium, Opium Tincture, OxyCODONE, OxyMORphone, Paregoric, Pentazocine, Remifentanil, SUFentanil, Tapentadol, TraMADol</p>\n</div> \n<p><b>Discussion</b> The acetaminophen maximum serum concentration (Cmax) was decreased by 15% to 56% with concurrent administration of an opioid.<sup>1,2,3,4</sup> This seems to reflect more of a delay in acetaminophen absorption than a net decrease in total exposure. Time to acetaminophen Cmax (Tmax) was increased by 1.5- to more than 9-fold.<sup>1,2,3,4</sup> Various studies of acetaminophen exposure and/or total excretion of acetaminophen have reported less of an effect with longer periods of observation, further supporting more of a delay than net decrease in absorption.<sup>1,2,3</sup><br><br>This interaction does appear to vary according to specific opioid used, with larger magnitude changes with morphine and meperidine than with tramadol, codeine, or anesthesia doses of alfentanil.<sup>1,2,3,4,5,6</sup> <br><br>Case series have also described this delayed acetaminophen absorption in patients with mixed overdoses of acetaminophen and opioids, with even some suggestion that this delayed acetaminophen absorption may be advantageous for minimizing the potential toxicity of the overdose.<sup>7,8</sup><br><br>The mechanism of this interaction is thought to be opioid-related impairment in gastric motility and gastric emptying leading to delayed, and possibly impaired, acetaminophen absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Yuan CS, Foss JF, O'Connor M, Roizen MF, Moss J. Effects of low-dose morphine on gastric emptying in healthy volunteers. <i>J Clin Pharmacol</i>. 1998;38(11):1017-1020. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9824782\">[PubMed 9824782]</a></p>\n<p>2. Crighton IM, Martin PH, Hobbs GJ, Cobby TF, Fletcher AJ, Stewart PD. A comparison of the effects of intravenous tramadol, codeine, and morphine on gastric emptying in human volunteers. <i>Anesth Analg</i>. 1998;87(2):445-449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9706948\">[PubMed 9706948]</a></p>\n<p>3. Nimmo WS, Heading RC, Wilson J, Tothill P, Prescott LF. Inhibition of gastric emptying and drug absorption by narcotic analgesics. <i>Br J Clin Pharmacol</i>. 1975;2(6):509-513. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9953\">[PubMed 9953]</a></p>\n<p>4. Kennedy JM, Tyers NM, Davey AK. The influence of morphine on the absorption of paracetamol from various formulations in subjects in the supine position, as assessed by TDx measurement of salivary paracetamol concentrations. <i>J Pharm Pharmacol</i>. 2003;55(10):1345-1350. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14607015\">[PubMed 14607015]</a></p>\n<p>5. Murphy DB, Sutton A, Prescott LF, Murphy MB. A comparison of the effects of tramadol and morphine on gastric emptying in man. <i>Anaesthesia</i>. 1997;52(12):1224-1229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9485982\">[PubMed 9485982]</a></p>\n<p>6. Milligan KR, Howe JP, McClean E, Dundee JW. Postoperative gastric emptying in outpatient anesthesia: the effect of opioid supplementation. <i>J Clin Anesth</i>. 1988;1(1):9-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3078526\">[PubMed 3078526]</a></p>\n<p>7. Reddick AD, Hodge K, Morrison WG. Effect of concomitant opiate ingestion on paracetamol levels in acute overdose. <i>Emerg Med J</i>. 2010;27(10):742-744. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20650915\">[PubMed 20650915]</a></p>\n<p>8. Muller FO, van Achterbergh SM, Hundt HK. Paracetamol overdose: protective effect of concomitantly ingested antimuscarinic drugs and codeine. <i>Hum Toxicol</i>. 1983;2(3):473-477. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6885092\">[PubMed 6885092]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8566":"<p><b>Title</b> Chloramphenicol (Systemic) / Acetaminophen</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acetaminophen may increase the serum concentration of Chloramphenicol (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor chloramphenicol therapy particularly closely if used together with acetaminophen, particularly monitoring patients for evidence of chloramphenicol toxicity.</p> \n<p><b>Discussion</b> The chloramphenicol half-life was prolonged by more than 4.6-fold (from 3.25 hours to 15 hours) with concurrent acetaminophen (100 mg IV) in a study of 6 adult patients being treated in an intensive care unit.<sup>1</sup> Conversely, studies in acutely ill children who were being treated with chloramphenicol with (n=8) or without (n=18) concurrent acetaminophen and in adults (n=5) being treated with chloramphenicol who were evaluated with and without acetaminophen both reported no significant differences in chloramphenicol pharmacokinetics associated with acetaminophen use.<sup>2,3</sup> Another study reported increased chloramphenicol clearance, decreased half-life, and decreased maximum serum concentration in children (n=5) who received both chloramphenicol (80 mg/kg/day IV) and acetaminophen (50 mg/kg/day, given every 6 hours).<sup>4</sup> It has been suggested that this conflicting finding may reflect simply the decrease in chloramphenicol concentrations that have been reported by some authors to happen between initial chloramphenicol doses and what is observed at steady-state.<sup>5</sup> Other studies of this interaction have, however, reported no significant differences between first-dose and steady-state pharmacokinetics of chloramphenicol.<sup>2</sup><br><br>The degree to which acetaminophen truly impacts chloramphenicol pharmacokinetics is unclear. Despite early reports of an increased chloramphenicol half-life with acetaminophen, more recent studies have reported either no change or a decrease in half-life, raising questions about the validity of previous reports. The mechanism for any such interaction is not certain, but acetaminophen inhibition of chloramphenicol glucuronidation is a possible explanation, as acetaminophen does undergo considerable conjugative metabolism, and thus could compete with other drugs for these metabolic enzymes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Buchanan N, Moodley GP. Interaction between chloramphenicol and paracetamol. <i>Br Med J</i>. 1979;2(6185):307-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=476439\">[PubMed 476439]</a></p>\n<p>2. Kearns GL, Bocchini JA Jr, Brown RD, Cotter DL, Wilson JT. Absence of a pharmacokinetic interaction between chloramphenicol and acetaminophen in children. <i>J Pediatr</i>. 1985;107(1):134-139. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4009329\">[PubMed 4009329]</a></p>\n<p>3. Stein CM, Thornhill DP, Neill P, Nyazema NZ. Lack of effect of paracetamol on the pharmacokinetics of chloramphenicol. <i>Br J Clin Pharmacol</i>. 1989;27(2):262-264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2713219\">[PubMed 2713219]</a></p>\n<p>4. Spika JS, Davis DJ, Martin SR, Beharry K, Rex J, Aranda JV. Interaction between chloramphenicol and acetaminophen. <i>Arch Dis Child</i>. 1986;61(11):1121-1124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3789791\">[PubMed 3789791]</a></p>\n<p>5. Choonara IA. Interaction between chloramphenicol and acetaminophen. <i>Arch Dis Child</i>. 1987;62(3):319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3566335\">[PubMed 3566335]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8567":"<p><b>Title</b> Orphenadrine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Orphenadrine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of orphenadrine with alcohol or other CNS depressants should be avoided.</p> \n<p><b>Discussion</b> The labeling for an orphenadrine and acetaminophen combination product cautions that concomitant use with alcohol or other CNS depressants should be avoided.<sup>1</sup> The reason for this warning appears to be the potential for additive or synergistic CNS depression due to the CNS depressant effects of orphenadrine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Norgesic (orphenadrine and paracetamol) [summary of product characteristics]. Chatswood, New South Wales, Australia: iNova Pharmaceuticals (Australia) Pty Limited; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8568":"<p><b>Title</b> Orphenadrine / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of orphenadrine with alcohol or other CNS depressants should be avoided.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The labeling for an orphenadrine and acetaminophen combination product cautions that concomitant use with alcohol or other CNS depressants should be avoided.<sup>1</sup> The reason for this warning appears to be the potential for additive or synergistic CNS depression due to the CNS depressant effects of orphenadrine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Norgesic</i> (orphenadrine and paracetamol) [summary of product characteristics]. Chatswood, New South Wales, Australia: iNova Pharmaceuticals (Australia) Pty Limited; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8569":"<p><b>Title</b> Belinostat / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Atazanavir may increase the serum concentration of Belinostat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concomitant use of atazanavir and belinostat should be avoided.</p> \n<p><b>Discussion</b> Use of atazanavir is contraindicated with drugs that are highly dependent on UGT1A1 for their clearance and for which increased concentrations are associated with serious adverse effects.<sup>1</sup> The belinostat prescribing information cautions that concomitant use with strong inhibitors of UGT1A1 should be avoided.<sup>2</sup><br><br>As a result of these warnings and that belinostat is primarily metabolized by UGT1A1 and atazanavir is an inhibitor of UGT1A1, use of this combination should be avoided.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p>2. <i>Beleodaq</i> (belinostat) [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals, Inc.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8570":"<p><b>Title</b> Anticoagulants / Omega-3 Fatty Acids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Omega-3 Fatty Acids may enhance the anticoagulant effect of Anticoagulants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving both omega-3 fatty acid-containing products (or even those changing their diets to substantially increase the content of omega-3 fatty acids) and an anticoagulant should be monitored for signs and symptoms of bleeding or excessive bruising.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for omega-3 fatty acid products advises cautious use whenever these agents are given to patients receiving drugs that impair coagulation.<sup>1,2</sup> <br><br>Omega-3 fatty acids may impair platelet function and prolong bleeding time independent of other coadministered drugs.<sup>1,2,3,4,5,6,7,8,9</sup> A few studies have suggested platelet-independent anticoagulant effects as well, based on reductions in antithrombin III (AT-III) concentrations,<sup>8</sup> thrombin-anti-thrombin III complex concentrations,<sup>10</sup> fibrinogen concentrations,<sup>11,12,13</sup> factor V concentrations,<sup>11</sup>, factor VII concentrations,<sup>13</sup> von Willebrand factor concentrations,<sup>13</sup> and thrombin generation.<sup>11</sup> A published case report describes an increase in INR in a warfarin-stable patient following the doubling of her fish oil dose from 1 g to 2 g daily,<sup>14</sup> suggesting a possible influence of the supplement on INR or warfarin disposition; however, a prescription omega-3 fatty acid supplement did not increase warfarin concentrations or anticoagulant effects in healthy volunteers.<sup>2</sup> Another published case report describes a 75 year old man taking warfarin (45 mg/week), aspirin (81 mg/day), and an unspecified omega-3 fatty acid supplement (6 g/day) who developed a subdural hematoma and parenchymal hemorrhages following a fall.<sup>15</sup> A clinical study of patients with sickle cell disease suggested that a reduction in pain episodes following initiation of omega-3 fatty acids (0.1 g/kg/d) may be mediated in part by reductions in thrombotic activity, as inferred based on decreases in d-dimer, prothrombin fragment 1.2, and plasmin-antiplasmin complex concentrations.<sup>16</sup><br><br>In contrast to much of the above, a 6 g/day dose of docosahexaenoic acid had no impact on platelet aggregation, prothrombin time (PT), activated partial thromboplastin time (aPTT), or AT-III concentrations in a study of healthy men.<sup>17</sup> Patients undergoing abdominal surgery who received parenteral nutrition (PN) containing 0.2 g/kg fish oil for 5 days had similar thromboplastin time, aPTT, fibrinogen, antithrombin III, factor VIIa, factor XIIa compared to patients whose PN contained no fish oil.<sup>18</sup> Patients with congestive heart failure given a 6 g/day dose of mixed eicosapentaenoic and docosahexaenoic acids for 2 months prior to coronary bypass surgery found no impact on PAI-1 concentrations,<sup>19</sup> while a 20 g single dose of mixed omega-3 fatty acids increased PAI-1 concentrations.<sup>20</sup> In 30 young adult males, an omega-3 supplement supplying 1.125 g/day eicosapentaenoic acid (also containing smaller amounts of docosahexaenoic acid, oleic acid, and palmitic acid) increased serum coagulation markers and decreased markers of fibrinolysis measured after physical exercise.<sup>21</sup> Finally, in healthy men given 6 g/day fish oil for 12 weeks was associated with a slight decrease in activated protein C ratio.<sup>22</sup><br><br>The above studies indicate relatively consistent antiplatelet effects of omega-3 fatty acids, with variable and likely context-sensitive effects on other coagulation mechanisms. The specific populations, supplements, regimens, and other factors that may predispose to adverse effects are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lovaza</i> (omega-3-acid ethyl esters) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2012.</p>\n<p>2. <i>Vascepa</i> (icosapent ethyl) [prescribing information]. Bedminster, NJ: Amarin Pharma Inc.; July 2012.</p>\n<p>3. Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. <i>Lancet</i>. 1981;2(8257):1190-1193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6118628\">[PubMed 6118628]</a></p>\n<p>4. Goodnight SH Jr, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. <i>Blood</i>. 1981;58(5):880-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7295999\">[PubMed 7295999]</a></p>\n<p>5. Hay CR, Durber AP, Saynor R. Effect of fish oil on platelet kinetics in patients with ischaemic heart disease. <i>Lancet</i>. 1982;1(8284):1269-1270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6123019\">[PubMed 6123019]</a></p>\n<p>6. Serebruany VL, Miller M, Pokov AN, et al. Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. <i>Cardiology</i>. 2011;118(3):187-194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21701167\">[PubMed 21701167]</a></p>\n<p>7. Freese R, Mutanen M. Alpha-linolenic acid and marine long-chain n-3 fatty acids differ only slightly in their effects on hemostatic factors in healthy subjects. <i>Am J Clin Nutr</i>. 1997;66(3):591-598. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9280178\">[PubMed 9280178]</a></p>\n<p>8. Sanders TA, Vickers M, Haines AP. Effect on blood lipids and haemostasis of a supplement of cod-liver oil, rich in eicosapentaenoic and docosahexaenoic acids, in healthy young men. <i>Clin Sci (Lond)</i>. 1981;61(3):317-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6266735\">[PubMed 6266735]</a></p>\n<p>9. Yoshimura T, Matsui K, Ito M, et al. Effects of highly purified eicosapentaenoic acid on plasma beta thromboglobulin level and vascular reactivity to angiotensin II. <i>Artery</i>. 1987;14(5):295-303. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2821970\">[PubMed 2821970]</a></p>\n<p>10. Shimizu H, Ohtani K, Tanaka Y, et al. Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate. <i>Thromb Haemost</i>. 1995;74(5):1231-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8607100\">[PubMed 8607100]</a></p>\n<p>11. Vanschoonbeek K, Feijge MA, Paquay M, et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation. <i>Arterioscler Thromb Vasc Biol</i>. 2004;24(9):1734-1740. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15217806\">[PubMed 15217806]</a></p>\n<p>12. Radack K, Deck C, Huster G. The comparative effects of n-3 and n-6 polyunsaturated fatty acids on plasma fibrinogen levels: a controlled clinical trial in hypertriglyceridemic subjects. <i>J Am Coll Nutr</i>. 1990;9(4):352-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2212394\">[PubMed 2212394]</a></p>\n<p>13. Shahar E, Folsom AR, Wu KK, et al. Associations of fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. The Atherosclerosis Risk in Communities (ARIC) Study. <i>Arterioscler Thromb</i>. 1993;13(8):1205-1212. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8343495\">[PubMed 8343495]</a></p>\n<p>14. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. <i>Ann Pharmacother</i>. 2004;38(1):50-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742793\">[PubMed 14742793]</a></p>\n<p>15. McClaskey EM, Michalets EL. Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. <i>Pharmacotherapy</i>. 2007;27(1):152-160. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17192169\">[PubMed 17192169]</a></p>\n<p>16. Tomer A, Kasey S, Connor WE, Clark S, Harker LA, Eckman JR. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. <i>Thromb Haemost</i>. 2001;85(6):966-974. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11434703\">[PubMed 11434703]</a></p>\n<p>17. Nelson GJ, Schmidt PS, Bartolini GL, Kelley DS, Kyle D. The effect of dietary docosahexaenoic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. <i>Lipids</i>. 1997;32(11):1129-1136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9397397\">[PubMed 9397397]</a></p>\n<p>18. Heller AR, Fischer S, Rossel T, et al. Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. <i>Br J Nutr</i>. 2002;87 Suppl 1:S95-101. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11895160\">[PubMed 11895160]</a></p>\n<p>19. Nilsen DW, Almdahl SM, Svensson B, Vaage J, Rasmussen K, Osterud B. Lipopolysaccharide induced monocyte thromboplastin synthesis and coagulation responses in patients undergoing coronary bypass surgery after preoperative supplementation with n-3 fatty acids. <i>Thromb Haemost</i>. 1993;70(6):900-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8165608\">[PubMed 8165608]</a></p>\n<p>20. Moller JM, Svaneborg N, Lervang HH, et al. The acute effect of a single very high dose of N-3 fatty acids on coagulation and fibrinolysis. <i>Thromb Res</i>. 1992;67(5):569-577. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1448789\">[PubMed 1448789]</a></p>\n<p>21. Sakamoto N, Nishiike T, Iguchi H, Sakamoto K. Effects of eicosapentaenoic acid intake on plasma fibrinolytic and coagulation activity by using physical load in the young. <i>Nutrition</i>. 2000;16(1):11-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10674228\">[PubMed 10674228]</a></p>\n<p>22. Englyst NA, Grimble RF, Byrne CD. Long-chain n-3 fatty acid supplementation in men increases resistance to activated protein C. <i>Metabolism</i>. 2007;56(4):547-551. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17379015\">[PubMed 17379015]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8571":"<p><b>Title</b> Agents with Antiplatelet Properties / Omega-3 Fatty Acids</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Omega-3 Fatty Acids may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients receiving both omega-3 fatty acid-containing products (or even those changing their diets to substantially increase the content of omega-3 fatty acids) and antiplatelet medications should be monitored for signs and symptoms of bleeding or excessive bruising.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Although the antiplatelet effects of the omega-3 fatty acids have been fairly well-documented in both human and animal/in vitro studies, only limited data exist regarding the interaction between omega-3 fatty acids and other antiplatelet agents. One study in 10 healthy men demonstrated that the antiplatelet effect of aspirin was at least additive with that of a fish-supplemented diet, and likely partially synergistic, with a prolongation in bleeding time that exceeding the sum of the prolongation seen with each treatment individually.<sup>1</sup> In a second study of healthy volunteers, administration of a prescription omega-3 fatty acid ethyl ester product increased the antiplatelet effects of aspirin, despite the omega-3 regimen alone having no measurable impact on platelet aggregation assays.<sup>2</sup> Results from both of these studies are consistent with findings from a study in rats showing that indomethacin further prolonged bleeding time in rats fed a diet supplemented with a fish oil concentrate.<sup>3</sup> All three papers suggest a complex mechanism behind the antiplatelet effects of omega-3 fatty acids that extends beyond inhibition of pro-aggregatory prostaglandin derivatives.<br><br>Regarding the antiplatelet effects of the omega-3 fatty acids, studies in both healthy volunteers<sup>1,4</sup> and patients with ischemic heart disease<sup>5</sup> or coronary artery disease<sup>6</sup> have reported significant antiplatelet effects associated with omega-3 fatty acids. These studies have documented that omega-3 fatty acids [equivalent to 0.5-3.5g/day of eicosapentaenoic acid (EPA)] prolong bleeding time, decrease both collagen- and ADP-induced platelet aggregation, and alter the platelet phospholipid fatty acid composition (i.e., increased ratio of omega-3:omega-6 fatty acids). Of note, data from these and other studies support the view that omega-3 fatty acids primarily influence platelet function by altering the interaction between platelets and the vascular wall.<sup>1,3,4,5,7</sup> Other possible effects reported from in vitro and animal studies include reduced platelet-activating factor (PAF), reduced generation of thromboxane B2, and antagonism of vasoconstriction at the site of vascular injury.<sup>3,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. <i>Lancet</i>. 1981;2(8257):1190-1193. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6118628\">[PubMed 6118628]</a></p>\n<p>2. Larson MK, Ashmore JH, Harris KA, et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. <i>Thromb Haemost</i>. 2008;100(4):634-641. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18841286\">[PubMed 18841286]</a></p>\n<p>3. Juan H, Sametz W. Fish oil diet rich in eicosapentaenoic acid increases bleeding time in the rat by interaction with sympathetic transmitters. <i>Agents Actions</i>. 1989;28(1-2):130-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2551150\">[PubMed 2551150]</a></p>\n<p>4. Goodnight SH Jr, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. <i>Blood</i>. 1981;58(5):880-885. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7295999\">[PubMed 7295999]</a></p>\n<p>5. Hay CR, Durber AP, Saynor R. Effect of fish oil on platelet kinetics in patients with ischaemic heart disease. <i>Lancet</i>. 1982;1(8284):1269-1270. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6123019\">[PubMed 6123019]</a></p>\n<p>6. Serebruany VL, Miller M, Pokov AN, et al. Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. <i>Cardiology</i>. 2011;118(3):187-194. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21701167\">[PubMed 21701167]</a></p>\n<p>7. Mayer K, Merfels M, Muhly-Reinholz M, et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. <i>Am J Physiol Heart Circ Physiol</i>. 2002;283(2):H811-818. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12124231\">[PubMed 12124231]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8572":"<p><b>Title</b> Thyroid Products / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may decrease the serum concentration of Thyroid Products. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients for decreased thyroid product effect (eg, elevated thyroid stimuating hormone [TSH], lethargy) if ciprofloxacin therapy is initiated. Consider separating administration by 6 hours.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 8 healthy volunteers, the thyroxine (T4) AUC decreased 39% when single doses of oral levothyroxine (1000 mcg) and ciprofloxacin (750 mg) were coadministered.<sup>1</sup> Two cases describe the development of hypothyroidism in stable levothyroxine treated patients after initiation of ciprofloxacin.<sup>2</sup> In one case, escalation of the levothyroxine dose failed to return the patient to a euthyroid state, and only after ciprofloxacin discontinuation did her hypothyroid state abate. In the second case, a euthyroid state was achieved only after the patient stopped taking the drugs simultaneously and instead separated their administration by 6 hours.<sup>2</sup><br><br>The mechanism of this potential interaction is not definitively known, but reduced absorption of levothyroxine by ciprofloxacin has been proposed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Goldberg AS, Tirona RG, Asher LJ, Kim RB, Van Uum SH. Ciprofloxacin and rifampin have opposite effects on levothyroxine absorption. <i>Thyroid</i>. 2013;23(11):1374-1378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23647409\">[PubMed 23647409]</a></p>\n<p>2. Cooper JG, Harboe K, Frost SK, Skadberg O. Ciprofloxacin interacts with thyroid replacement therapy. <i>BMJ</i>. 2005;330(7498):1002. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15860826\">[PubMed 15860826]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8573":"<p><b>Title</b> ALPRAZolam / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of ALPRAZolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor patients receiving fluvoxamine for increased effects of alprazolam. Reduced alprazolam doses may be required in some cases.</p> \n<p><b>Discussion</b> In a clinical study of 60 healthy men (30 smokers, 30 nonsmokers), coadministration of fluvoxamine (50 mg daily for 3 days, then 100 mg daily for 7 days) increased alprazolam (1 mg 4 times daily, starting on fluvoxamine day 7) AUCs on day 1 and 4 of coadministration by 26% and 96%, respectively.<sup>1</sup> Fluvoxamine AUCs were similar between groups on the first day of dosing (no alprazolam), but were 24% lower on day 10 of treatment in subjects given alprazolam. Two other clinical studies found smaller average increases (53% to 58%) in alprazolam point concentration/dose ratios in patients receiving fluvoxamine.<sup>2,3</sup><br><br>The suspected primary mechanism of this interaction is fluvoxamine inhibition of CYP3A4 mediated alprazolam metabolism. The mechanism by which alprazolam may reduce fluvoxamine exposure is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. <i>Eur J Clin Pharmacol</i>. 1994;46(1):35-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8005185\">[PubMed 8005185]</a></p>\n<p>2. Suzuki Y, Shioiri T, Muratake T, et al. Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. <i>Eur J Clin Pharmacol</i>. 2003;58(12):829-833. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12698310\">[PubMed 12698310]</a></p>\n<p>3. Sugahara H, Maebara C, Ohtani H, et al. Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease. <i>Eur J Clin Pharmacol</i>. 2009;65(7):699-704. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19225771\">[PubMed 19225771]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8574":"<p><b>Title</b> Thyroid Products / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cimetidine may decrease the serum concentration of Thyroid Products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> In a study of 20 female patients with simple goiter, administration of cimetidine (400 mg single dose) reduced absorption of radiolabeled levothyroxine (dose not stated) by 20.6%.<sup>1</sup> Administration of levothyroxine with ranitidine (300 mg single dose) had no effect on levothyroxine absorption.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown. Reduced gastric acidity may be responsible for reduced levothyroxine absorption, despite no observed decrease in absorption with concomitant ranitidine. Higher levothyroxine dose requirements have been noted in patients with conditions of impaired gastric acid secretion (eg, <i>Helicobacter pylori</i> or atrophic gastritis),<sup>2</sup> and in a retrospective analysis, thyroid-stimulating hormone (TSH) levels rose significantly in patients on a stable levothyroxine dose after lansoprazole initiation.<sup>3</sup> However, two other pharmacokinetic studies found no changes in TSH or the AUC of thyroxine (T4) when administered with famotidine, esomeprazole, or pantoprazole.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jonderko G, Jonderko K, Marcisz C, Kotulska A. Effect of cimetidine and ranitidine on absorption of [125]levothyroxine administered orally. <i>Zhongguo Yao Li Xue Bao</i>. 1992;13(5):391-394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1300037\">[PubMed 1300037]</a></p>\n<p>2. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. <i>N Engl J Med</i>. 2006;354(17):1787-1795. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16641395\">[PubMed 16641395]</a></p>\n<p>3. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. <i>Endocr Pract</i>. 2007;13(4):345-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17669709\">[PubMed 17669709]</a></p>\n<p>4. Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. <i>Horm Metab Res</i>. 2006;38(1):57-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16477543\">[PubMed 16477543]</a></p>\n<p>5. Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. <i>Thyroid</i>. 2008;18(5):493-498. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18466075\">[PubMed 18466075]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8575":"<p><b>Title</b> Thyroid Products / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Thyroid Products. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> One study enrolled 123 patients treated with levothyroxine for nontoxic multinodular goiter who also displayed clinical features suggestive of reduced gastric acid secretion (eg, <i>Helicobacter pylori</i> or atrophic gastritis) and compared them with 135 control patients treated with levothyroxine with no signs of reduced gastric acid secretion. <sup>1</sup> In order to maintain the desired thyroid-stimulating hormone (TSH) concentration, daily doses of levothyroxine were 22% to 34% higher in patients with reduced acid secretion compared with patients with unchanged gastric acidity. As an additional analysis, 10 patients had their TSH and levothyroxine doses evaluated before and after treatment with omeprazole 40 mg daily. Similar to overall trial results, levothyroxine doses were 37% higher during omeprazole therapy in order to maintain similar TSH levels.<sup>1</sup> A retrospective analysis compared 37 patients receiving stable levothyroxine doses for 6 months who subsequently were started on lansoprazole with 55 control patients on stable levothyroxine doses who did not receive proton pump inhibitor (PPI) therapy.<sup>2</sup> TSH levels increased 30% in patients who received lansoprazole and were essentially unchanged (less than a 6% change) in control patients. In a database analysis, median serum TSH concentrations were 0.12 mIU/L greater in the 6 months following PPI initiation compared with the previous year in 887 patients receiving stable levothyroxine doses.<sup>3</sup> TSH concentrations following PPI initiation increased by at least 5 mIU/L in 5.6% of patients, and decreased by at least 5 mIU/L in 3.2% of patients.<br><br>In contrast, one pharmacokinetic study found no change in TSH or the AUC of thyroxine (T4) or free-T4 when levothyroxine (4 mcg/kg single dose) was given after pantoprazole therapy (40 mg daily for 7 days) in 20 volunteers.<sup>4</sup> Another study (N=30) found no change in levothyroxine (600 mcg single dose) absorption or the AUC of T4 when administered following a 7 day course of esomeprazole (40 mg daily) or famotidine (20 mg twice daily).<sup>5</sup> Similarly, there was no statistically significant difference in TSH levels between baseline (ie, pre-omeprazole) and post-omeprazole or between patients taking low dose omeprazole (20 mg daily) and patients taking high dose omeprazole (40 mg daily) in this study of of 19 patients receiving a stable dose of levothyroxine dose and with TSH levels within normal limits for at least 1 year prior to omeprazole.<sup>6</sup><br><br>The proposed mechanism of this potential interaction is impairment of thyroid product absorption in the presence of elevated gastric pH. However, thyroid product absorption is variable and influenced by numerous factors (eg, age, dietary habits, concomitant disease states, interacting medications).<sup>1</sup> It is unknown what role these factors may have played in the results of the analyses suggesting an interaction between PPIs and thyroid products since those analyses were either retrospective or not specifically designed to assess this interaction. Other data have suggested that a drug interaction between these agents is dependent on use of one or more specific levothyroxine tablet formulations.<sup>7</sup> However, the findings and generalizability of all analyses suggesting an interaction are questionable because the two pharmacokinetic studies investigating the interaction found no impact of PPI or other gastric-acid-reducing treatment on thyroid product absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, <i>Helicobacter pylori</i> infection, and chronic gastritis. <i>N Engl J Med</i>. 2006;354(17):1787-1795. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16641395\">[PubMed 16641395]</a></p>\n<p>2. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. <i>Endocr Pract</i>. 2007;13(4):345-349. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17669709\">[PubMed 17669709]</a></p>\n<p>3. Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS). <i>Clin Endocrinol (Oxf)</i>. 2015;82(1):136-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25040647\">[PubMed 25040647]</a></p>\n<p>4. Dietrich JW, Gieselbrecht K, Holl RW, Boehm BO. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. <i>Horm Metab Res</i>. 2006;38(1):57-59. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16477543\">[PubMed 16477543]</a></p>\n<p>5. Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. <i>Thyroid</i>. 2008;18(5):493-498. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18466075\">[PubMed 18466075]</a></p>\n<p>6. Abi-Abib Rde C, Vaisman M. Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole? <i>Arq Bras Endocrinol Metabol</i>. 2014;58(7):731-736. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25372582\">[PubMed 25372582]</a></p>\n<p>7. Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4481-4486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25259910\">[PubMed 25259910]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8576":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Aprepitant</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Duration</b>: Single 40 mg oral aprepitant doses do not substantially inhibit CYP3A4 and are not expected to participate in this interaction. Most other single aprepitant doses (aprepitant 125 mg or fosaprepitant 100-150 mg) appear to only weakly inhibit CYP3A4, while longer regimens (eg, 125 mg aprepitant, then 80 mg daily for 4 days) may cause moderate inhibition.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aprepitant may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of CYP3A4 substrates (decreased effects for prodrugs activated by CYP3A4) when given during or within the first few days following aprepitant. These effects are expected to be greatest when aprepitant is administered for several days. Single 40 mg aprepitant doses are not expected to substantially alter CYP3A4-mediated metabolism.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In clinical studies summarized in aprepitant and fosaprepitant US prescribing information, administration of these agents altered midazolam exposure in the following ways: a single 100 mg fosaprepitant dose increased the AUC of midazolam (2 mg single oral dose) given on the same day by 1.6 fold; a single 150 mg fosaprepitant dose increased the AUC of midazolam (2 mg single oral dose) given on the same day by 1.8 fold, but had no impact on the AUC of a second midazolam dose given 3 days later; a single 125 mg aprepitant dose increased the AUC of midazolam (2 mg single intravenous dose) given 1 hour after aprepitant by 1.5 fold; a 5 day aprepitant regimen (125 mg once, then 80 mg daily for 4 days) increased the AUC of midazolam (2 mg single oral dose) given on the first day or aprepitant by 2.3 fold and increased the AUC midazolam given on the last day of aprepitant by 3.3 fold; and a 3 day aprepitant regimen (125 mg once, then 80 mg daily for 2 days) increased the AUC of midazolam (2 mg single intravenous dose) given the day after aprepitant completion by 25%, decreased the AUC of midazolam given 5 days after aprepitant completion by 19%, and decreased the AUC of midazolam given 12 days after the completion of aprepitant by 4%.<sup>1,2,3</sup><br><br>The suspected primary mechanisms of interaction between these agents is aprepitant inhibition of CYP3A4 mediated midazolam metabolism. Aprepitant may also exert some weak CYP3A4 induction that can persist for several days following discontinuation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Emend</i> (aprepitant/fosaprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; March 2013.</p>\n<p>2. Majumdar AK, Yan KX, Selverian DV, et al. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. <i>J Clin Pharmacol</i>. 2007;47(6):744-750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17463213\">[PubMed 17463213]</a></p>\n<p>3. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. <i>Clin Pharmacol Ther</i>. 2003;74(2):150-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891225\">[PubMed 12891225]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8577":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Fosaprepitant</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Duration</b>: Single aprepitant doses (aprepitant 125 mg or fosaprepitant 100-150 mg) appear to only weakly inhibit CYP3A4 mediated metabolism. Longer regimens (eg, 125 mg aprepitant, then 80 mg daily for 4 days) may cause moderate inhibition.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosaprepitant may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for increased effects of CYP3A4 substrates (decreased effects for prodrugs activated by CYP3A4) when given during or within the first few days following fosaprepitant. These effects are expected to be greatest when fosaprepitant is administered for several days.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In clinical studies summarized in aprepitant and fosaprepitant US prescribing information, administration of these agents altered midazolam exposure in the following ways: a single 100 mg fosaprepitant dose increased the AUC of midazolam (2 mg single oral dose) given on the same day by 1.6 fold; a single 150 mg fosaprepitant dose increased the AUC of midazolam (2 mg single oral dose) given on the same day by 1.8 fold, but had no impact on the AUC of a second midazolam dose given 3 days later; a single 125 mg aprepitant dose increased the AUC of midazolam (2 mg single intravenous dose) given 1 hr after aprepitant by 1.5 fold; a 5 day aprepitant regimen (125 mg once, then 80 mg daily for 4 days) increased the AUC of midazolam (2 mg single oral dose) given on the first day or aprepitant by 2.3 fold and increased the AUC midazolam given on the last day of aprepitant by 3.3; and a 3 day aprepitant regimen (125 mg once, then 80 mg daily for 2 days) increased the AUC of midazolam (2 mg single intravenous dose) given the day after aprepitant completion by 25%, decreased the AUC of midazolam given 5 days after aprepitant completion by 19%, and decreased the AUC of midazolam given 12 days after the completion of aprepitant by 4%.<sup>1,2,3</sup><br><br>The suspected primary mechanisms of interaction between these agents is aprepitant inhibition of CYP3A4 mediated midazolam metabolism. Aprepitant may also exert some weak CYP3A4 induction that can persist for several days following discontinuation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Emend</i> (aprepitan/fosaprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; March 2013.</p>\n<p>2. Majumdar AK, Yan KX, Selverian DV, et al. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. <i>J Clin Pharmacol</i>. 2007;47(6):744-750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17463213\">[PubMed 17463213]</a></p>\n<p>3. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. <i>Clin Pharmacol Ther</i>. 2003;74(2):150-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891225\">[PubMed 12891225]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8578":"<p><b>Title</b> C1 inhibitors / Androgens</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Androgens may enhance the thrombogenic effect of C1 inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for serious thromboembolic events if a C1 inhibitor is combined with androgens.</p>\n<div>\n <p><b>Androgens Interacting Members</b> Danazol, Fluoxymesterone, Mesterolone, MethylTESTOSTERone, Nandrolone, Oxandrolone, Oxymetholone, Testosterone</p>\n <p><b>C1 inhibitors Interacting Members</b> C1 Inhibitor (Human), C1 Inhibitor (Recombinant)</p>\n</div> \n<p><b>Discussion</b> Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 inhibitor products, particularly in patients with risk factors, including the use of androgens.<sup>1,2,3</sup> Additional serious TE events have been reported during post-marketing surveillance<sup>4</sup> and when C1 inhibitors were used at higher than recommended doses.<sup>5</sup> <br><br>Product labeling recommends that the benefits of treatment of hereditary angioedema attacks should be weighed against the risks of TE events in patients with known risk factors (eg, androgen use),<sup>1,2</sup> and to monitor these patients for TE events during and after C1 inhibitor administration.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Berinert</i> (C1 esterase inhibitor [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; February 2014.</p>\n<p>2. <i>Cinryze</i> (C1 esterase inhibitor [human]) [prescribing information]. Exton, PA: ViroPharma Biologics Inc; February 2014.</p>\n<p>3. <i>Ruconest</i> (C1 esterase inhibitor [recombinant]) [prescribing information]. Raleigh, NC: Santarus Inc; July 2014.</p>\n<p>4. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Association adverse event reporting system database. <i>Pharmacotherapy</i>. 2012;32(10):902-909. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23033229\">[PubMed 23033229]</a></p>\n<p>5. Horstick G, Berg O, Heimann A, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. <i>Circulation</i>. 2001;104(25):3125-3131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11748112\">[PubMed 11748112]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8579":"<p><b>Title</b> C1 inhibitors / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for serious thromboembolic events if a C1 inhibitor is combined with estrogen derivatives.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n <p><b>C1 inhibitors Interacting Members</b> C1 Inhibitor (Human), C1 Inhibitor (Recombinant)</p>\n</div> \n<p><b>Discussion</b> Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 inhibitor products, particularly in patients with risk factors, including the use of oral contraceptives (eg, estrogen derivatives).<sup>1,2,3</sup> Additional serious TE events have been reported during post-marketing surveillance<sup>4</sup> and when C1 inhibitors were used at higher than recommended doses.<sup>5</sup> <br><br>Product labeling recommends that the benefits of treatment of hereditary angioedema attacks should be weighed against the risks of TE events in patients with known risk factors (eg, estrogen use),<sup>1,2</sup> and to monitor these patients for TE events during and after C1 inhibitor administration.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Berinert</i> (C1 esterase inhibitor [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; February 2014.</p>\n<p>2. <i>Cinryze</i> (C1 esterase inhibitor [human]) [prescribing information]. Exton, PA: ViroPharma Biologics Inc; February 2014.</p>\n<p>3. <i>Ruconest</i> (C1 esterase inhibitor [recombinant]) [prescribing information]. Raleigh, NC: Santarus Inc; July 2014.</p>\n<p>4. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Association adverse event reporting system database. <i>Pharmacotherapy</i>. 2012;32(10):902-909. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23033229\">[PubMed 23033229]</a></p>\n<p>5. Horstick G, Berg O, Heimann A, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. <i>Circulation</i>. 2001;104(25):3125-3131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11748112\">[PubMed 11748112]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8580":"<p><b>Title</b> C1 inhibitors / Progestins</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Progestins may enhance the thrombogenic effect of C1 inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for serious thromboembolic events if a C1 inhibitor is combined with progestins.</p>\n<div>\n <p><b>Progestins Interacting Members</b> Chlormadinone, Cyproterone, Desogestrel, Dienogest, Drospirenone, Dydrogesterone, Ethynodiol Diacetate, Etonogestrel, Gestodene, HYDROXYprogesterone Caproate, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Megestrol, Norelgestromin, Norethindrone, Norgestimate, Norgestrel, Progesterone</p>\n <p><b>C1 inhibitors Interacting Members</b> C1 Inhibitor (Human), C1 Inhibitor (Recombinant)</p>\n</div> \n<p><b>Discussion</b> Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 inhibitor products, particularly in patients with risk factors, including the use of oral contraceptives (eg, progestins).<sup>1,2,3</sup> Additional serious TE events have been reported during post-marketing surveillance<sup>4</sup> and when C1 inhibitors were used at higher than recommended doses.<sup>5</sup> <br><br>Product labeling recommends that the benefits of treatment of hereditary angioedema attacks should be weighed against the risks of TE events in patients with known risk factors (eg, progestin use),<sup>1,2</sup> and to monitor these patients for TE events during and after C1 inhibitor administration.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Berinert</i> (C1 esterase inhibitor [human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; February 2014.</p>\n<p>2. <i>Cinryze</i> (C1 esterase inhibitor [human]) [prescribing information]. Exton, PA: ViroPharma Biologics Inc; February 2014.</p>\n<p>3. <i>Ruconest</i> (C1 esterase inhibitor [recombinant]) [prescribing information]. Raleigh, NC: Santarus Inc; July 2014.</p>\n<p>4. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Association adverse event reporting system database. <i>Pharmacotherapy</i>. 2012;32(10):902-909. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23033229\">[PubMed 23033229]</a></p>\n<p>5. Horstick G, Berg O, Heimann A, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. <i>Circulation</i>. 2001;104(25):3125-3131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11748112\">[PubMed 11748112]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8586":"<p><b>Title</b> Nitrazepam / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Nitrazepam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for decreased therapeutic effects of nitrazepam if rifampin is initiated/dose increased, or increased effects if rifampin is discontinued/dose decreased. When possible, consider alternatives to rifampin or nitrazepam, or increases in initial nitrazepam doses.</p> \n<p><b>Discussion</b> In a clinical study of 16 healthy volunteers, coadministration of rifampin (600 mg/day for 7 days) increased the clearance of nitrazepam by 83%.<sup>1</sup> The mechanism of this interaction is unknown. One in vitro study found indirect evidence of CYP3A4 metabolism of nitrazepam,<sup>2</sup> but other clinical data suggest at most a minor role of this enzyme in nitrazepam metabolism.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Brockmeyer NH, Mertins L, Klimek K, Goos M, Ohnhaus EE. Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1990;28(9):387-393. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2228325\">[PubMed 2228325]</a></p>\n<p>2. Mizuno K, Katoh M, Okumura H, et al. Metabolic activation of benzodiazepines by CYP3A4. <i>Drug Metab Dispos</i>. 2009;37(2):345-351. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19005028\">[PubMed 19005028]</a></p>\n<p>3. Luurila H, Olkkola KT, Neuvonen PJ. Interaction between erythromycin and nitrazepam in healthy volunteers. <i>Pharmacol Toxicol</i>. 1995;76(4):255-258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7617555\">[PubMed 7617555]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8587":"<p><b>Title</b> Disulfiram / Atazanavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Atazanavir may diminish the therapeutic effect of Disulfiram. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients for reduced disulfiram effects/increased dose requirements during concomitant treatment with atazanavir.</p> \n<p><b>Discussion</b> In a clinical study of 20 healthy volunteers, coadministration of atazanavir (400 mg/day for 12 days) had no impact on pharmacokinetic variables for disulfiram (62.5 mg/day for 8 days, then 250 mg/day for 4 days, with pharmacokinetic/dynamic sampling on days 4 and 12) or its carbamate metabolite.<sup>1</sup> However, disulfiram did not significantly decrease peripheral blood mononuclear cell aldehyde dehydrogenase activity in subjects receiving atazanavir, while it decreased activity by 44% in subjects given placebo. The mechanism of this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. McCance-Katz EF, Gruber VA, Beatty G, et al. Interaction of disulfiram with antiretroviral medications: Efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism [published online October 11, 2013]. <i>Am J Addict</i>. doi:10.1111/j.1521-0391.2013.12081.x. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24118434\">[PubMed 24118434]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8588":"<p><b>Title</b> Ezetimibe / Fenofibrate and Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fenofibrate and Derivatives may enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Coadminister fenofibrate and ezetimibe with caution, and monitor for evidence of myopathy and cholelithiasis. Ezetimibe and fenofibrate should both be discontinued if there is evidence of myopathy. If cholelithiasis is suspected, conduct gallbladder studies and consider alternative lipid lowering therapy.</p> \n<p><b>Discussion</b> Coadministration of fenofibrate with ezetimibe has been associated with an increased incidence of hepatic transaminase elevations and cholecystectomy, and may be associated with an increased risk of myopathy.<sup>1,2</sup> Additionally, in a published clinical study, coadministration of fenofibrate (200 mg daily for 14 days) increased the maximum concentration and AUC of ezetimibe by 64% and 48%, respectively.<sup>1,3</sup> Consistent changes were seen in a second pharmacokinetic study as well.<sup>4</sup> The mechanism responsible for these pharmacokinetic changes is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zetia</i> (ezetimibe) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; January 2012.</p>\n<p>2. <i>Ezetrol</i> (ezetimibe) [product monograph]. Kirkland, QC: Merck Canada Inc; March 2012.</p>\n<p>3. Kosoglou T, Statkevich P, Fruchart JC, et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. <i>Curr Med Res Opin</i>. 2004;20(8):1197-1207. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15324522\">[PubMed 15324522]</a></p>\n<p>4. Gustavson LE, Schweitzer SM, Burt DA, et al. Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. <i>Clin Ther</i>. 2006;28(3):373-387. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16750452\">[PubMed 16750452]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8589":"<p><b>Title</b> Ezetimibe / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemfibrozil may enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Gemfibrozil may increase the serum concentration of Ezetimibe. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of ezetimibe and gemfibrozil is not recommended according to US and Canadian product labeling. Whenever a fibrate is used in combination with ezetimibe, both drugs should be discontinued if there is evidence of myopathy.</p> \n<p><b>Discussion</b> US and Canadian labeling for ezetimibe states that its use in combination with fibrates other than fenofibrate is not recommended, based on a relative lack of clinical data supporting such use.<sup>1,2</sup> Coadministration of any fibrate with ezetimibe is expected to elevate the risk of cholelithiasis and rhabdomyolysis.<sup>1,2</sup> Additionally, in a clinical study of 12 healthy men, coadministration of gemfibrozil (600 mg every 12 hours for 7 days) increased the maximum concentration and AUC of total ezetimibe (following ezetimibe 10 mg daily for 7 days) by 91% and 64%, respectively.<sup>1,2,3</sup> The mechanism of this latter interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zetia</i> (ezetimibe) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; January 2012.</p>\n<p>2. <i>Ezetrol</i> (ezetimibe) [product monograph]. Kirkland, QC: Merck Canada Inc; March 2012.</p>\n<p>3. Reyderman L, Kosoglou T, Statkevich P, et al. Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. <i>Int J Clin Pharmacol Ther</i>. 2004;42(9):512-518. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15487810\">[PubMed 15487810]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8590":"<p><b>Title</b> Ezetimibe / Bezafibrate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bezafibrate may enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of ezetimibe and bezafibrate is not recommended per US and Canadian product labeling. Whenever a fibrate is used in combination with ezetimibe, both drugs should be discontinued if there is evidence of myopathy.</p> \n<p><b>Discussion</b> US and Canadian labeling for ezetimibe states that its use in combination with fibrates other than fenofibrate is not recommended, based on a relative lack of clinical data supporting such use.<sup>1,2</sup> Coadministration of any fibrate with ezetimibe is expected to elevate the risk of cholelithiasis and rhabdomyolysis.<sup>1,2</sup> At least one observational study does, however, provide some support for the potential safety and efficacy of bezafibrate use in combination with ezetimibe (incidence of creatine phosphokinase elevations, 1.5%; myalgia, 0.8%; and asymptomatic gallstones, 0.6%).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zetia</i> (ezetimibe) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; January 2012.</p>\n<p>2. <i>Ezetrol</i> (ezetimibe) [product monograph]. Kirkland, QC: Merck Canada Inc; March 2012.</p>\n<p>3. Teramoto T, Abe K, Taneyama T. Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. <i>Cardiovasc Diabetol</i>. 2013;12:163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24195788\">[PubMed 24195788]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8591":"<p><b>Title</b> Alcohol (Ethyl) / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mianserin may enhance the CNS depressant effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving mianserin should avoid use of alcohol, due to the potential for additive cognitive and motor impairment. This risk appears to be greatest during initiation of mianserin.</p> \n<p><b>Discussion</b> The objective effects of alcohol administration were enhanced on day 1 of mianserin administration but not on day 8 of mianserin in a study of 13 healthy volunteers who received mianserin (10 to 30 mg twice daily for 8 days) and alcohol (1 g/kg on days 1 and 8, each 2 hours after the mianserin dose).<sup>1</sup> The mianserin summary of product characteristics (SPC) also cautions that concurrent use with alcohol could resuslts in enhanced CNS depressant effects, including greater impairment of concentration and psychomotor skills, particularly early in the course of mianserin treatment.<sup>2,3,4</sup> Some SPCs also recommend that patients be advised to avoid alcohol during mianserin treatment,<sup>2,3</sup> while others do not specifically recommend avoidance.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Seppala T, Stromberg C, Bergman I. Effects of zimeldine, mianserin and amitriptyline on psychomotor skills and their interaction with ethanol a placebo controlled cross-over study. <i>Eur J Clin Pharmacol</i>. 1984;27(2):181-189. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6238829\">[PubMed 6238829]</a></p>\n<p>2. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>3. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>4. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8592":"<p><b>Title</b> Mianserin / Monoamine Oxidase Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of mianserin with a monoamine oxidase inhibitor (MAOI) is contraindicated. Mianserin should not be started until at least 14 days after stopping a MAOI, and a MAOI should not be started until 7 to 14 days of stopping mianserin.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> According to different mianserin summaries of product characteristics, concurrent use with a monoamine oxidase inhibitor (MAOI) should be avoided and/or is contraindicated, as is both the use of mianserin within 14 days of stopping a MAOI and the use of a MAOI within 7 to 14 days of stopping mianserin.<sup>1,2,3</sup> Use of these agents together may result in serotonin syndrome, which is the basis for this warning.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>2. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>3. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8593":"<p><b>Title</b> CarBAMazepine / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Mianserin may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Mianserin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of decreased clinical response to mianserin when using this combination. Mianserin dose adjustments may be necessary. Additionally, mianserin may decrease the seizure threshold, increasing the likelihood of a seizure, particularly in patients with other risk factors for seizure activity.</p> \n<p><b>Discussion</b> The concentrations of total R- and S-mianserin were an average of 55% to 56% lower following initiation of carbamazepine (400 mg/day for 4 weeks) to patients (n=12) receiving mianserin 60 mg/day.<sup>1</sup> Serum mianserin concentrations were also on average 30% lower among users of concurrent carbamazepine (n=4) as compared to matched controls who were not receiving carbamazepine.<sup>2</sup><br><br>An additional concern with this combination is the potential for mianserin to decrease the seizure threshold,<sup>3,4,5,6</sup> an effect that may increase the potential for seizure activity in carbamazepine-treated patients, particularly in those patients with other risk factors for seizure activity.<br><br>The mechanism(s) for this potential interaction is/are uncertain. Carbamazepine is a known inducer of CYP3A4 and other metabolic enzymes, so induction of mianserin metabolism is at least one likely mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Eap CB, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. <i>Ther Drug Monit</i>. 1999;21(2):166-170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10217335\">[PubMed 10217335]</a></p>\n<p>2. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. <i>J Clin Psychopharmacol</i>. 1991;11(5):313-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1765574\">[PubMed 1765574]</a></p>\n<p>3. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>4. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>5. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>6. Borowicz KK, Banach M, Zarczuk R, Lukasik D, Luszczki JJ, Czuczwar SJ. Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. <i>Psychopharmacology (Berl)</i>. 2007;195(2):167-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17653694\">[PubMed 17653694]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8594":"<p><b>Title</b> Barbiturates / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mianserin may enhance the CNS depressant effect of Barbiturates. Mianserin may diminish the therapeutic effect of Barbiturates. Barbiturates may decrease the serum concentration of Mianserin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of mianserin with barbiturates is not recommended according to the summary of product characteristics for at least one mianserin product, but this specific warning is not common to all products. If this combination is used, monitor patients for both excessive CNS depression as well as for evidence of decreased clinical response to mianserin. Mianserin dose adjustments may be necessary. Additionally, mianserin may decrease the seizure threshold, increasing the likelihood of a seizure, particularly in patients with other risk factors for seizure activity.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> The use of mianserin with barbiturates is not recommended according to the summary of product characteristics (SPC) for at least one mianserin product,<sup>1</sup> but this specific warning is not common to all products.<sup>2,3</sup> This listed warning appears to be out of concern for excessive CNS depression with the combination.<sup>1</sup><br><br>Additional concerns with this combination are the potential for barbiturates, generally regarded as inducers of CYP3A and other metabolic enzymes, to reduce concentrations of mianserin and the potential for mianserin to decrease the seizure threshold, increasing the likelihood of a seizure, particularly in patients with other risk factors for seizure activity.<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>2. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p>3. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>4. Borowicz KK, Banach M, Zarczuk R, Lukasik D, Luszczki JJ, Czuczwar SJ. Acute and chronic treatment with mianserin differentially affects the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. <i>Psychopharmacology (Berl)</i>. 2007;195(2):167-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17653694\">[PubMed 17653694]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8595":"<p><b>Title</b> Alpha2-Agonists (Ophthalmic) / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Mianserin may diminish the therapeutic effect of Alpha2-Agonists (Ophthalmic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of mianserin with apraclonidine or brimonidine is not recommended according to the summary of product characteristics for at least one mianserin product, but this specific warning is not common to all products. If this combination cannot be avoided, monitor patients for decreased clinical response to the ophthalmic alpha2-agonist.</p>\n<div>\n <p><b>Alpha2-Agonists (Ophthalmic) Interacting Members</b> Apraclonidine, Brimonidine (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> The use of mianserin with the ophthalmic alpha2-agonists apraclonidine or brimonidine is not recommended according to the summary of product characteristics for at least one mianserin product,<sup>1</sup> but this specific warning is not common to all products.<sup>2,3</sup><br><br>The specific concern behind this listed warning is not stated, but given the alpha2-antagonist actions of mianserin, opposing actions at the alpha2 receptors may be responsible.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>2. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>3. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8596":"<p><b>Title</b> Vitamin K Antagonists / Mianserin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Mianserin may enhance the anticoagulant effect of Vitamin K Antagonists. Mianserin may diminish the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> No change in phenprocoumon response or dose requirement was noted with concurrent mianserin in a study of 63 subjects who received dose-adjusted phenprocoumon for 5 weeks and who were randomly assigned to mianserin 30 mg/day, mianserin 60 mg/day, or matching placebo.<sup>1</sup> However, a case report describes a patient whose acenocoumarin dose requirement increased following initiation of mianserin, though it was also noted that newly-initiated amiodarone may also have played a role in the possible interaction.<sup>2</sup> The summary of product characteristics for several mianserin products notes that patients taking coumarin-type anticoagulants may require close monitoring while receiving mianserin.<sup>3,4,5</sup><br><br>The specific mechanism for any possible interaction is uncertain as mianserin is not known to be a clinically significant inhibitor of any drug metabolism enzymes, despite the statement in various summaries of product characteristics that mianserin may affect the metabolism of coumarin-type anticoagulants such as warfarin.<sup>4,5</sup> Additionally, mianserin may have some serotoninergic activity,<sup>3,4,5</sup> and antidepressants such as the serotonin specific reuptake inhibitors and some tricyclic antidepressants have been shown to inhibit platelet activation, possibly increasing the risk for bleeding. Thus, mianserin-related decreases in platelet function may increase the risk for bleeding when combined with anticoagulants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kopera H, Schenk H, Stulemeijer S. Phenprocoumon requirement, whole blood coagulation time, bleeding time and plasma gamma-GT in patients receiving mianserin. <i>Eur J Clin Pharmacol</i>. 1978;13(5):351-356. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27373\">[PubMed 27373]</a></p>\n<p>2. Baettig D, Tillement JP, Baumann P. Interaction between mianserin and acenocoumarin: a single case study. <i>Int J Clin Pharmacol Ther</i>. 1994;32(4):165-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8032574\">[PubMed 8032574]</a></p>\n<p>3. Mianserin [summary of product characteristics]. Eastbourne, East Sussex, United Kingdom: Teva UK Limited; April 2012.</p>\n<p>4. <i>Tolvon</i> (mianserin) [summary of product characteristics]. South Granville, New South Wales, Australia: Merck Sharpe &amp; Dohme (Australia) Pty Limited; December 2013.</p>\n<p>5. <i>Lumin</i> (mianserin) [summary of product characteristics]. Millers Point, New South Wales, Australia: Alphapharm Pty Limited; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8597":"<p><b>Title</b> Warfarin / Cyclophosphamide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cyclophosphamide may decrease the serum concentration of Warfarin. Cyclophosphamide may increase the serum concentration of Warfarin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required beyond traditional INR monitoring that accompanies standard warfarin therapy.</p> \n<p><b>Discussion</b> One case report describes a 72-year old female who maintained a therapeutic prothrombin time (PT) of 23 seconds (control 11 seconds) while taking oral cyclophosphamide 450 mg daily and warfarin 5 mg daily.<sup>1</sup> Cyclophosphamide was discontinued and warfarin 5 mg daily was continued. On day 9 after cyclophosphamide discontinuation, her PT rose to 51 seconds requiring vitamin K administration despite a warfarin dose reduction to 2.5 mg daily on day 7. The mechanism for this potential interaction is unknown, but cyclophosphamide-mediated CYP3A4 induction may play a role.<sup>2</sup><br><br>Cyclophosphamide has also been implicated in cases of exaggerated warfarin response, but the role of cyclophosphamide is difficult to determine as regimens contained multiple chemotherapeutic agents, particularly 5-fluorouracil, an agent often implicated in warfarin related drug-drug interactions.<sup>3,4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tashima CK. Cyclophosphamide effect on coumarin anticoagulation. <i>South Med J</i>. 1979;72(5):633-634. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=441785\">[PubMed 441785]</a></p>\n<p>2. Martin H, Sarsat JP, de Waziers I, et al. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. <i>Pharm Res</i>. 2003;20(4):557-568. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12739762\">[PubMed 12739762]</a></p>\n<p>3. Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Shiller JH. Warfarin-5-FU interaction--a consecutive case series. <i>Pharmacotherapy</i>. 1999;19(12):1445-1449. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10600095\">[PubMed 10600095]</a></p>\n<p>4. Seifter EJ, Brooks BJ Jr, Urba WJ. Possible interactions between warfarin and antineoplastic drugs. <i>Cancer Treat Rep</i>. 1985;69(2):244-245. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3971397\">[PubMed 3971397]</a></p>\n<p>5. Booth BW, Weiss RB. Venous thrombosis during adjuvant chemotherapy. <i>N Engl J Med</i>. 1981;305(3):170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7242590\">[PubMed 7242590]</a></p>\n<p>6. Magagnoli M, Masci G, Castagna L, Morenghi E, Santoro A. High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. <i>Ann Oncol</i>. 2006;17(1):174-176. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16100233\">[PubMed 16100233]</a></p>\n<p>7. Davis DA, Fugate SE. Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-fluorouracil therapy. <i>Pharmacotherapy</i>. 2005;25(3):442-447. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15843293\">[PubMed 15843293]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8598":"<p><b>Title</b> Warfarin / Erlotinib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Erlotinib may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased warfarin effect (elevated INR, bleeding) if erlotinib is initiated and monitor for decreased warfarin effects if erlotinib is discontinued.</p> \n<p><b>Discussion</b> A case report describes a 47-year old man taking warfarin 2.5 mg daily with fairly stable INR control (2.1-3.2) who experienced an elbow hematoma and an INR of 9.1 soon after starting erlotinib therapy.<sup>1</sup> Of note, the patient also experienced severe diarrhea with the initiation of erlotinib. Product labeling for erlotinib in the US and Canada also warns that INR elevations and bleeding events have been reported during clinical trials with erlotinib and that patients should be monitored for changes in INR during concomitant therapy.<sup>2,3</sup><br><br>The mechanism of this interaction is unknown, but the authors of the above case report hypothesize it may relate to protein-displacement, vitamin K absorption disruption due to erlotinib induced diarrhea, or competition for CYP 3A4 metabolic elimination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thomas KS, Billingsley A, Amarshi N, Nair BA. Elevated international normalized ratio associated with concomitant warfarin and erlotinib. <i>Am J Health Syst Pharm</i>. 2010;67(17):1426-1429. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20720241\">[PubMed 20720241]</a></p>\n<p>2. <i>Tarceva</i> (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals LLC; April 2014.</p>\n<p>3. <i>Taceva</i> (erlotinib) [product monograph]. Mississauga, Ontario, Canada: OSI Pharmaceuticals Inc; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8599":"<p><b>Title</b> Warfarin / Vemurafenib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vemurafenib may increase the serum concentration of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased warfarin effects (elevated INR, bleeding) if vemurafenib is initiated. Monitor for decreased warfarin effects if vemurafenib is discontinued.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in both the vemurafenib US and Canadian product labeling, vemurafenib (960 mg twice daily for 15 days) when combined with a single dose of warfarin (dose not stated) increased the AUC of S-warfarin (the more potent enantiomer) by 18% to 23% and increased the half-life of S-warfarin by 5 hours.<sup>1,2</sup> The manufacturers state that caution should be exercised and additional INR monitoring considered when vemurafenib is administered with warfarin.<br><br>The likely mechanism of this interaction is vemurafenib-mediated CYP 2C9 inhibition of S-warfarin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zelboraf</i> (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; March 2014.</p>\n<p>2. <i>Zelboraf</i> (vemurafenib) [product monograph]. Mississaua, Ontario, Canada: Hoffmann-La Roche Limited; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}